Information on EC 2.7.11.22 - cyclin-dependent kinase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)

The enzyme appears in viruses and cellular organisms

EC NUMBER
COMMENTARY
2.7.11.22
-
RECOMMENDED NAME
GeneOntology No.
cyclin-dependent kinase
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT ACCESSION NO.
LITERATURE
ATP + a protein = ADP + a phosphoprotein
show the reaction diagram
-
-
-
-
ATP + a protein = ADP + a phosphoprotein
show the reaction diagram
catalytic aspartate residue
-
ATP + a protein = ADP + a phosphoprotein
show the reaction diagram
activation involves the activation loop, a polypeptide region outside the active site cleft, which is reversibly phosphorylated at a Thr residue, phosphorylation leads to enzyme inhibition
-
ATP + a protein = ADP + a phosphoprotein
show the reaction diagram
reaction mechanism
-
ATP + a protein = ADP + a phosphoprotein
show the reaction diagram
active site amino acid sequences of PK5 and mrk
-
REACTION TYPE
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
phospho group transfer
-
-
-
-
SYSTEMATIC NAME
IUBMB Comments
ATP:cyclin phosphotransferase
Activation of cyclin-dependent kinases requires association of the enzyme with a regulatory subunit referred to as a cyclin. It is the sequential activation and inactivation of cyclin-dependent kinases, through the periodic synthesis and destruction of cyclins, that provides the primary means of cell-cycle regulation.
SYNONYMS
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
A-type CDK
-
-
A-type cyclin-dependent kinase
-
-
A-type cyclin-dependent kinase A
-
-
B-type cyclin-dependent kinase
-
-
B-type cyclin-dependent kinase
-
-
CCRK
Q9JHU3
-
CDC2 kinase
P13863
-
CDC2 kinase
-
-
cdc2 PK
-
-
CDC2-like serine/threonine-protein kinase CRP
P34117
-
cdc2-related kinase
P34556
-
cdc28p
Saccharomyces cerevisiae YOC3388
-
-
-
Cdc28p-Chlp kinase
-
-
CDC2a
P24100
-
CDC2deltaT
P06493
a variant of human CDC2, that lacks 171 nucleotides corresponding to 57 amino acids, which compose most of the T-loop
cdc2MsB
Q05006
-
Cdc2p complex
P04551
-
CDK
-
-
CDK
Emericella nidulans
-
-
CDK
-
-
CDK
-
-
CDK
Q9JHU3
-
CDK
Saccharomyces cerevisiae YOC3388
-
-
-
Cdk 2
-
-
cdk-5
-
-
Cdk-A
-
-
Cdk1
-
-
cdk1 kinase
-
-
Cdk1/Cyclin B
-
-
cdk1/cyclin B1 complex
-
-
Cdk1/cyclin B1 kinase
-
-
CDK10
-
-
CDK11
-
-
CDK11p110
P21127
-
CDK2
P24941
main CDK involved in G1 to S phase transition
CDK2
Q00535
-
CDK2
-
-
CDK2
P97377
-
CDK2L
O55076
-
CDK3
-
-
CDK4
-
-
CDK4
P11802
-
CDK4 kinase
-
-
Cdk5
-
-
Cdk5
Q00535
-
Cdk5
P49615
-
Cdk5
Mus musculus ICR
-
-
-
Cdk5
Q03114
-
Cdk5
P51166
-
CDK5 homolog
P48609
-
Cdk5-p35
-
-
CDK5/p25
-
-
cdk5/p25 kinase
-
-
cdk6
-
-
cdk7
-
-
cdk7
P50613
-
cdk7
P50613
subunit of the transcription/DNA repair factor TFIIH
cdk7
Q03147
-
CDK9
P50750
-
CDK9
P50750
CDK9 is a cdc2-like Ser/Thr kinase whose complexes with T- and K-type cyclins constitute the basal transcription factor P-TEFb
CDKA
Physcomitrella patens Gransden-2004
-
-
-
CDKA1
Q8GVD8
-
CDKA;1
Arabidopsis thaliana Col-0
-
-
-
CDKB1
Q8GVD7
-
CDKC1
Q6I5Y0
CDK9-like protein
CDKC2
Q5JK68
CDK9-like protein
CDKC2
Q8W4P1
combines the functions of both CRK7 and CDK9, and can also couple splicing with transcription
cell division control protein 2
P54119
-
cell division control protein 2
Emericella nidulans
Q00646
-
cell division control protein 2
P04551
-
cell division control protein 2 cognate
P23573
-
cell division control protein 2 homolog
P48734
-
cell division control protein 2 homolog
P34556
-
cell division control protein 2 homolog
Q01917
-
cell division control protein 2 homolog
P34112
-
cell division control protein 2 homolog
P13863
-
cell division control protein 2 homolog
P06493
-
cell division control protein 2 homolog
P11440
-
cell division control protein 2 homolog
Q07785
-
cell division control protein 2 homolog
Q9W739
-
cell division control protein 2 homolog
P39951
-
cell division control protein 2 homolog
P23111
-
cell division control protein 2 homolog 1
P38973
-
cell division control protein 2 homolog 1
P35567
-
cell division control protein 2 homolog 2
Q05006
-
cell division control protein 2 homolog 2
P54665
-
cell division control protein 2 homolog 2
P24033
-
cell division control protein 2 homolog 3
P54666
-
cell division control protein 2 homolog A
Q38772
-
cell division control protein 2 homolog A
P24100
-
cell division control protein 2 homolog B
P25859
-
cell division control protein 2 homolog C
Q38774
-
cell division control protein 2 homolog D
Q38775
-
cell division control protein 28
P43063
-
cell division control protein 28
P00546
-
cell division cycle 2-related protein kinase 7
Q9NYV4
-
cell division protein kinase 10
Q15131
-
cell division protein kinase 2
P43450
-
cell division protein kinase 2
O55076
-
cell division protein kinase 2
P48963
-
cell division protein kinase 2
Q63699
-
cell division protein kinase 2 homolog
Q04770
-
cell division protein kinase 2 homolog
P23437
-
cell division protein kinase 2 homolog CRK1
Q06309
-
cell division protein kinase 3
Q00526
-
cell division protein kinase 4
P11802
-
cell division protein kinase 4
P30285
-
cell division protein kinase 4
P35426
-
cell division protein kinase 5
Q02399
-
cell division protein kinase 5
Q00535
-
cell division protein kinase 5
P49615
-
cell division protein kinase 5
Q03114
-
cell division protein kinase 5
P51166
-
cell division protein kinase 5 homolog
P48609
-
cell division protein kinase 6
Q00534
-
cell division protein kinase 7
P54685
-
cell division protein kinase 7
P50613
-
cell division protein kinase 7
Q03147
-
cell division protein kinase 7
P20911
-
cell division protein kinase 9
P50750
-
CRK4 protein kinase
Q03147
-
CTD kinase alpha subunit
Q03957
-
cyclin A-cyclin-dependent kinase 2
-
-
cyclin A-dependent protein kinase 2
-
-
cyclin A/Cdk2
-
-
cyclin activating kinase
-
-
cyclin dependent kinase 2
-
-
cyclin dependent kinase 2
-
-
cyclin-dependent kinase
-
-
cyclin-dependent kinase
Q9JHU3
-
cyclin-dependent kinase
-
-
cyclin-dependent kinase 1
P06493
-
cyclin-dependent kinase 11p110
P21127
-
cyclin-dependent kinase 11p58
-
-
cyclin-dependent kinase 2
P24941
-
cyclin-dependent kinase 2
Q00535
-
cyclin-dependent kinase 2
P97377
-
cyclin-dependent kinase 4
-
-
cyclin-dependent kinase 4
P35426
-
cyclin-dependent kinase 5
-
-
cyclin-dependent kinase 5
-
-
cyclin-dependent kinase 5
Q00535
-
cyclin-dependent kinase 5
P49615
-
cyclin-dependent kinase 5
Mus musculus ICR
-
-
-
cyclin-dependent kinase 5
Q03114
-
cyclin-dependent kinase 5
P51166
-
cyclin-dependent kinase 5-p35
-
-
cyclin-dependent kinase 5/p39
-
-
cyclin-dependent kinase 6
-
-
cyclin-dependent kinase 7
P50613
as part of the CDK-activating kinase complex, CDK7 is a component of the basal transcription factor TFIIH
cyclin-dependent kinase 7
Q03147
as part of the CDK-activating kinase complex, CDK7 is a component of the basal transcription factor TFIIH
cyclin-dependent kinase 8
P49336
-
cyclin-dependent kinase 9
P50750
-
cyclin-dependent kinase 9
P50750
part of the positive transcription elongation factor b
cyclin-dependent kinase A
-
-
cyclin-dependent kinase A
-
-
cyclin-dependent kinase A
Physcomitrella patens Gransden-2004
-
-
-
cyclin-dependent kinase A
-
-
cyclin-dependent kinase activating kinase
-
-
cyclin-dependent kinase C
Q5JK68, Q6I5Y0
-
Cyclin-dependent kinase pef1
-
-
-
-
cyclin-dependent kinase-2
-
-
cyclin-dependent kinase-2
-
-
cyclin-dependent kinase-2
P24941
-
cyclin-dependent kinase-5
-
-
cyclin-dependent kinase-5
-
-
cyclin-dependent kinase-8
-
-
cyclin-dependent kinases 7
-
-
cyclin-dependent kinases 9
-
-
cyclin-dependent protein kinase
-
-
cyclin-dependent protein kinase 5
-
-
Eph-related receptor protein tyrosine kinase
P30285
-
G1/S cyclin-dependent kinase
-
-
G1/S cyclin-dependent kinase
Saccharomyces cerevisiae YOC3388
-
-
-
G2-specific protein kinase nim-1
P48479
-
G2-specific protein kinase NIMA
Emericella nidulans
P11837
-
galactosyltransferase associated protein kinase p58/GTA
P21127
-
galactosyltransferase associated protein kinase p58/GTA
P24788
-
galactosyltransferase associated protein kinase p58/GTA
P46892
-
glycogen synthase kinase-3alphabeta
-
-
K-cyclin/cdk6 kinase
-
-
K35
P49336
-
kinase Cdk6
Q00534
-
KSHV cyclin
-
-
male germ cell-associated kinase
P20794
-
male germ cell-associated kinase
P20793
-
meiosis induction protein kinase IME2/SME1
P32581
-
meiotic mRNA stability protein kinase UME5
P39073
-
negative regulator of the PHO system
P17157
-
NIMA protein kinase
Emericella nidulans
P11837
-
p25-Cdk5 kinase complex
-
-
p27 cyclin dependent kinase
-
-
p34cdc2
Q04770
-
p34cdc2 homologue
P23111
-
p34cdc2 protein kinase
Emericella nidulans
Q00646
-
p34cdc2 protein kinase
P04551
-
p40MO15
P50613
-
p40MO15
P20911
-
p42
Q9JHU3
-
p58clk-1 protein kinase
P21127
-
PCTAIRE 2
O35831
-
PCTAIRE-3
Q04899
-
PFTK1
-
-
PFTK1/CCND3 complex
-
-
PHO85
-
multifunctional cyclin-dependent protein kinase
PHO85 homolog
-
-
-
-
PHOA
Emericella nidulans
-
-
PHOB
Emericella nidulans
-
-
phosphate-activated cyclin-dependent kinase
-
-
phosphate-activated cyclin-dependent kinase
-
-
-
phosphate-sensing CDK
-
-
phosphate-sensing CDK
-
-
-
PISSLRE
Q15131
-
PITALRE
P50750
-
PITSLRE
P21127
formerly
PNQALRE
Q9JHU3
-
Prk1 protein kinase
O13958
-
protein kinase csk1
P36615
-
serine/threonine kinase p
O76039
-
serine/threonine protein kinase PCTAIRE-3
Q07002
-
serine/threonine protein kinase PITSLRE
Q9VPC0
-
serine/threonine protein kinase SGV1
P23293
-
serine/threonine-protein kinase ALS2CR7
Q96Q40
-
serine/threonine-protein kinase CAK1
P43568
-
serine/threonine-protein kinase KIN28
P06242
-
serine/threonine-protein kinase KKIALRE
Q00532
-
serine/threonine-protein kinase MAK
P20794
-
serine/threonine-protein kinase MAK
Q04859
-
serine/threonine-protein kinase MAK
P20793
-
serine/threonine-protein kinase MHK
P43294
-
serine/threonine-protein kinase PCTAIRE-1
Q00536
-
serine/threonine-protein kinase PCTAIRE-1
Q04735
-
serine/threonine-protein kinase PCTAIRE-2
Q00537
-
serine/threonine-protein kinase PCTAIRE-2
O35831
-
serine/threonine-protein kinase PCTAIRE-3
Q04899
-
serine/threonine-protein kinase PCTAIRE-3
O35832
-
serine/threonine-protein kinase pef1
O74456
-
serine/threonine-protein kinase prk1
O13958
-
STK9
O76039
-
UL97 protein
-
has activities similar to cellular cyclin-cyclin-dependent kinase complexes
MO15/CDK7
P50613
-
additional information
-
see also EC 2.7.11.26
additional information
-
the enzyme belongs to the PITSLRE kinase family
additional information
-
CDK5 is a unique member of the CDK family, see also EC 2.7.11.26; the enzyme belongs to the CDK family
additional information
-
see also EC 2.7.11.1 and EC 2.7.11.22
additional information
-
see also EC 2.7.11.26
additional information
-
see also EC 2.7.11.26
CAS REGISTRY NUMBER
COMMENTARY
150428-23-2
-
ORGANISM
COMMENTARY
LITERATURE
SEQUENCE CODE
SEQUENCE DB
SOURCE
ecotype Columbia
-
-
Manually annotated by BRENDA team
ecotype Columbia Col-0
SwissProt
Manually annotated by BRENDA team
gene CDKB1,1
-
-
Manually annotated by BRENDA team
Arabidopsis thaliana Col-0
-
-
-
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
African green monkey
-
-
Manually annotated by BRENDA team
zebrafish
-
-
Manually annotated by BRENDA team
common squid
-
-
Manually annotated by BRENDA team
Emericella nidulans
-
SwissProt
Manually annotated by BRENDA team
Emericella nidulans
-
SwissProt
Manually annotated by BRENDA team
Emericella nidulans
several strains
-
-
Manually annotated by BRENDA team
CDKA1; Jerusalem artichoke
SwissProt
Manually annotated by BRENDA team
CDKB1; Jerusalem artichoke
SwissProt
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
alpha2-2 isozyme
SwissProt
Manually annotated by BRENDA team
cdk1, cdk2, cdk5, cdk7, and cdk9
-
-
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
C57BL6/129SVJ and FVBN wild-type mice
-
-
Manually annotated by BRENDA team
ICR mice
-
-
Manually annotated by BRENDA team
radiation-sensitive strain BALB/c and the radiation-resistant strain C57BL
-
-
Manually annotated by BRENDA team
Mus musculus ICR
ICR mice
-
-
Manually annotated by BRENDA team
marine unicellular green algae strain isolated from the Thau lagoon, cyclin-dependent kinases CDKB and CDKA, as well as cyclin A and cyclin B are single copy genes, probably two isoforms of CDKA exist
-
-
Manually annotated by BRENDA team
isozymes CDKA;1, and CDKA;2
-
-
Manually annotated by BRENDA team
Physcomitrella patens Gransden-2004
isozymes CDKA;1, and CDKA;2
-
-
Manually annotated by BRENDA team
strains D6 and W2
-
-
Manually annotated by BRENDA team
pregnant Wistar rats
-
-
Manually annotated by BRENDA team
SpragueDawley rats
-
-
Manually annotated by BRENDA team
Wistar rats
-
-
Manually annotated by BRENDA team
strain YOC3388
-
-
Manually annotated by BRENDA team
strains W303 and S288C and derivatives
-
-
Manually annotated by BRENDA team
Saccharomyces cerevisiae YOC3388
strain YOC3388
-
-
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
contains two type A CDKs
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
evolution
-
cyclin-dependent kinase 5 belongs to a family of proline-directed serine/threonine kinases
evolution
-
primate herpesviruses, including the oncogenic Kaposi sarcoma herpesvirus, encode cyclinDhomologues. Viral cyclins have diverged from their cellular progenitor in that they elicit holoenzyme activity independent of activating phosphorylation by the CDK-activating kinase and resistant to inhibition by CDK inhibitors
evolution
-
cyclin-dependent kinase 5, Cdk5, is a member of the family of Cdks. Cdks are proline-directed Ser/Thr protein kinases that are activated by binding a regulatory subunit called cyclin, comparison of neuronal and cycling Cdks, overview. Cdk5 may have evolved from cycling Cdks to function in post-mitotic neurons
malfunction
-
cdk5 knockdown results in supernumerary spinal and cranial motor neurons. While a dominant negative, kinase-dead cdk5 promotes the generation of supernumerary motor neurons, over-expression of cdk5 suppresses motor neuron development
malfunction
-
the inhibition of cdk-5 activity has neuroprotective effect on neurons in Niemann-Pick disease type C mice
malfunction
-
inhibition of cyclin-dependent kinases 7 and 9 drives apoptosis to promote resolution of inflammation, CDK and protein synthesis inhibitors induce neutrophil apoptosis, overview. Cdk inhibitor R-roscovitine affects global gene transcription in LPS-stimulated and -unstimulated primary human neutrophils, overview
malfunction
-
differentiated SHSY5Y cells and human neurons show increased cell death from DNA damage induced by camptothecin treatment when Cdk5 is knocked down with siRNA. Increased sensitivity against UV-irradiation is also observed in neurons and other terminally differentiated cells such as podocytes when the expression of Cdk5 and its activators p35 or cyclin I are reduced with siRNA. Knockout of Cdk5 or p35 results in inverted layers of neurons in the cerebral cortex. Longterm inactivation of Cdk5 triggers cell death as well as hyperactivation of Cdk5 by p25. Pro-death activity is suppressed by membrane association of Cdk5 via myristoylation of p35
malfunction
-
Cdk5 null mice exhibit perinatal lethality with abnormal positioning of neurons in the brain. Ballooned perikarya of large neurons in the brainstem and cytoplasmic vacuoles in brain nuclei are described for Cdk5 null mice. Similar phenotypes were also observed in the p35-/- p39-/- double null mutant
malfunction
-
treatment of leaf cells with a CDK inhibitor or induction of dominant-negative CDKA1 protein inhibits not only cell cycle progression but also tip growth and protonemal gene expression
malfunction
-
inhibition of CDK activity at the shoot apex results in premature differentiation of shoot apical meristem cells. Cell-cycle inhibition in the STM domain affects cell division in the meristem and the developing organs
malfunction
Arabidopsis thaliana Col-0
-
inhibition of CDK activity at the shoot apex results in premature differentiation of shoot apical meristem cells. Cell-cycle inhibition in the STM domain affects cell division in the meristem and the developing organs
-
malfunction
Physcomitrella patens Gransden-2004
-
treatment of leaf cells with a CDK inhibitor or induction of dominant-negative CDKA1 protein inhibits not only cell cycle progression but also tip growth and protonemal gene expression
-
metabolism
-
the primary cellular mechanism that restricts cyclin D1/CDK4 activity is cytoplasmic, ubiquitin-mediated degradation of cyclin D1 during S-phase. Mutations that disrupt this event, via within the cyclin D1 degron or inactivating the cyclin D1 E3 ligase, Fbx4, directly contribute to neoplastic growth
metabolism
-
cyclin-dependent kinases 7 and 9 specifically regulate neutrophil transcription
metabolism
-
cell cycle regulation is characterized by alternating activities of cyclin-dependent kinases and of the ubiquitin ligase anaphase promoting complex/cyclosome, overview. The latter is inhibited during S-phase by early mitotic inhibitor 1, which is negatively regulated by phosphorylation through CDKs, allowing the accumulation of cyclins A and B and to prevent re-replication, overview
metabolism
-
cycling Cdks and neuronal Cdk5 are inversely expressed during neuronal differentiation. Upon neuronal differentiation, cycling Cdks, which are active in proliferating neuronal precursor cells, are down-regulated and Cdk5-p35 is upregulated
metabolism
-
S595 phosphorylation may globally couple the cell cycle machinery to regulatory pathways that impact eEF2K activity, eEF2 S595 phosphorylation is increased in mitosis. Cyclin A-CDK2 shuttles from the cytoplasm to the nucleus and could phosphorylate eEF2 in interphase cells
metabolism
-
activity of cyclin-dependent kinase A links cell cycle reactivation and the acquisition of new cell-type characteristics during reprogramming in the moss Physcomitrella patens, overview. Cell cycle progression is not required for acquisition of protonema cell-type characteristics
metabolism
-
cyclin-dependent kinase subunit 1 and 2 natural overexpression in human mammary epithelial and breast cancer-derived cells, as well as in other cell types, leads to override of the intra-S-phase checkpoint that blocks DNA replication in response to replication stress. Specifically, binding of Cks1 or Cks2 to cyclin-dependent kinase 2 confers partial resistance to the effects of inhibitory tyrosine phosphorylation mediated by the intra-S-phase checkpoint, allowing cells to continue replicating DNA even under conditions of replicative stress, a mechanism contributing to tumor development. Cks protein overexpression does not affect checkpoint signaling through modulation of Cdk2 inhibitory phosphorylation
physiological function
-
cdk5 plays a critical role in spinal and cranial motor neuron development
physiological function
-
CDK1 and CDK2 have integral roles in the cell cycle, putative roles in transcriptional regulation and a controversial role in apoptosis. CDK5 is involved in apoptosis, transcription, differentiation, and endocytosis. CDK7 is a CDK-activating kinase responsible for enhancing the kinase activity of CDK1 and 2. CDK7 associated with cyclin H and MAT1 is responsible for initiation of transcription by the holoenzyme RNA Pol II. Regulation of transcription of Mcl-1 and involvement in pivotal inflammatory signalling via NF-kappaB are functions of CDK7 and CDK9. CDK4 and CDK6 are required for progression through G1 phase. CDK3 is implicated in G0 exit and G1/S phase transition in the cell cycle, CDK10 has a role in transition from G2 to M phase. CDK11 has potentially dual roles in transcription that do not involve direct phosphorylation of RNA polymerase II C-terminal domain.
physiological function
-
nuclear cyclin D1/CDK4-dependent repression of CUL4A and CUL4B, encoding scaffolding proteins for the E3 ligase that directs CDT1 degradation during S-phase, the repression requires S-phase accumulation of catalytically active cyclin D1/CDK4, molecular mechanism, overview. Cyclin D1/CDK4 can increase histone methyltransferase activity of PRMT5/MEP50, a PRMT5 co-regulatory factor, through phosphorylation of Thr5 and perhaps through Ser264, and increased PRMT5 activity mediates key events associated with cyclin D1-dependent neoplastic growth including CUL4 repression, CDT1 overexpression, and DNA re-replication. Cyclin D1T286A/CDK4 regulates PRMT5 methyltransferase activity via MEP50 phosphorylation, overview
physiological function
-
nuclear cyclin D1/CDK4-dependent repression of CUL4A and CUL4B, encoding scaffolding proteins for the E3 ligase that directs CDT1 degradation during S-phase, the repression requires S-phase accumulation of catalytically active cyclin D1/CDK4, molecular mechanism, overview. Phosphorylation of MEP50, a PRMT5 co-regulatory factor, by CDK4 increases PRMT5/MEP50 activity, and increased PRMT5 activity mediates key events associated with cyclin D1-dependent neoplastic growth including CUL4 repression, CDT1 overexpression, and DNA re-replication
physiological function
-
cyclin-dependent kinases 7 and 9 specifically regulate neutrophil transcription, overview
physiological function
-
role of CDK2 cytoplasmic relocalization in the antiproliferative effects of 1,25-dihydroxyvitamin D3. Central roles for CDK2 nuclear-cytoplasmic trafficking and cyclin E in the mechanism of 1,25-dihydroxyvitamin D3-mediated growth inhibition in prostate cancer cells
physiological function
-
CDK-mediated phosphorylation of early mitotic inhibitor 1 prevents its binding to ubiquitin ligase anaphase promoting complex/cyclosome
physiological function
-
cyclin/cyclin-dependent kinase (CDK) complexes are critical regulators of cellular proliferation. A complex network of regulatory mechanisms has evolved to control their activity, including activating and inactivating phosphorylation of the catalytic CDK subunit and inhibition through specific regulatory proteins, molecular mechanism, overview
physiological function
-
primate herpesviruses, including the oncogenic Kaposi sarcoma herpesvirus, encode cyclinDhomologues. Viral cyclins have diverged from their cellular progenitor in that they elicit holoenzyme activity independent of activating phosphorylation by the CDK-activating kinase and resistant to inhibition by CDK inhibitors, molecular mechanism, overview
physiological function
-
Cdk5 regulates multiple neuronal activities neuronal migration, neurite extension, and synapse formation during brain development, as well as in synaptic activities in mature neurons and neuronal cell death in neurodegenerative diseases, and it controls life and death of the neuronal cells, pro-death activities of Cdk5-p25, overview. Knockdown of Cdk5 by siRNA reduces the number of Rohon-Beard spinal sensory neurons and increases the number of apoptotic neurons in the brain. When global ischemia is induced by occlusion, Cdk5 death activity occurs in the cytoplasm but not in the nucleus, thus the pro-death activity of Cdk5 depends on the cellular localization of the active Cdk5 complex and death signaling. Cdk5 is required for phosphorylation of signal transduction and activation of transcription 3, STAT3, also related to the pathogenesis of Alzheimer's disease, Cdk5-p35 activity functions as a survival factor in a cell-death model of neurodegenerative disorders. Up-regulated Cdk5 induces phosphorylation of STAT3 at Ser727 to bind the BACE1 promoter, which enhances BACE1 transcription and leads to an increase in protein and activity of BACE1, ultimately resulting in amyloid beta production. Cdk5-p25 phosphorylates p53 on Ser15, Ser33, and Ser44, and phosphorylated p53 is prevented from Hdm-2-mediated ubiquitination and proteasomal degradation in SH-SY5Y cells
physiological function
-
Cdk5 appears to be involved in the regulation of neuronal survival both during neuronal development and under stress conditions
physiological function
-
PP2A enhancement of CDK8 is independent of RV-cyclin expression and likely plays a role in the normal regulation of CDK8
physiological function
-
the phosphate-activated cyclin-dependent kinase Pho85 stabilizes G1 cyclin to trigger cell cycle entry, Pho85 does not control Cln3 stability through regulation of autophagy. The activity of Pho85 is essential for accumulating Cln3 and for reentering the cell cycle after phosphate refeeding. Cln3 is a molecular target of the Pho85 kinase that is required to modulate cell cycle entry in response to environmental changes in nutrient availability
physiological function
-
Ser595 phosphorylation of eukaryotic elongation factor 2 (eEF2) by cyclin A-cyclin-dependent kinase 2 regulates its inhibition by eEF2 kinase through T56 phosphorylation. S595 phosphorylation varies during the cell cycle and is required for efficient T56 phosphorylation in vivo, T56 phosphorylation inactivates eEF2 and is the only known normal eEF2 functional modification. S595 phosphorylation facilitates T56 phosphorylation by recruiting eEF2K to eEF2.
physiological function
-
the activity of cyclin-dependent kinase A links cell cycle reactivation and the acquisition of new cell-type characteristics during reprogramming in the moss Physcomitrella patens, overview. Leaf cells facing the cut undergo CDK activation along with induction of a D-type cyclin, tip growth, and transcriptional activation of protonema-specific genes, CDKA regulates protonema-specific genes and tip growth, as well as cell cycle progression and other cellular changes in parallel. But iozymes CDKA;1 and CDKA;2 are expressed before cutting and activated afterwards
physiological function
-
a specific G2/M form of Cdc28 can phosphorylate in vitro the N-terminal region of Rad9 on nine consensus CDK phosphorylation sites, N-terminal CDK consensus sites are phosphorylated by Cdc28/Clb2 and are required for activation of Chk1. The integrity of CDK consensus sites and the activity of Cdc28 are required for both the activation of the Chk1 checkpoint kinase and its interaction with Rad9. Phosphorylation of T143 is the most important feature promoting Rad9/Chk1 interaction, while the much more abundant phosphorylation of the neighbouring T125 residue impedes the Rad9/Chk1 interaction. CDK-dependent activation of Chk1 controls Rad9/Chk1 interaction
physiological function
-
CDK9 is a component of the P-TEFb complex involved in transcriptional regulation. CDK9 activity is a key regulator of neutrophil lifespan, preventing apoptosis by maintaining levels of short lived anti-apoptotic proteins such as Mcl-1. Upon association with its activating partner cyclin T1, CDK9 forms P-TEFb, a general transcription factor responsible for phosphorylating the C-terminal domain of RNA polymerase II
physiological function
Physcomitrella patens Gransden-2004
-
the activity of cyclin-dependent kinase A links cell cycle reactivation and the acquisition of new cell-type characteristics during reprogramming in the moss Physcomitrella patens, overview. Leaf cells facing the cut undergo CDK activation along with induction of a D-type cyclin, tip growth, and transcriptional activation of protonema-specific genes, CDKA regulates protonema-specific genes and tip growth, as well as cell cycle progression and other cellular changes in parallel. But iozymes CDKA;1 and CDKA;2 are expressed before cutting and activated afterwards
-
physiological function
-
the phosphate-activated cyclin-dependent kinase Pho85 stabilizes G1 cyclin to trigger cell cycle entry, Pho85 does not control Cln3 stability through regulation of autophagy. The activity of Pho85 is essential for accumulating Cln3 and for reentering the cell cycle after phosphate refeeding. Cln3 is a molecular target of the Pho85 kinase that is required to modulate cell cycle entry in response to environmental changes in nutrient availability
-
metabolism
Physcomitrella patens Gransden-2004
-
activity of cyclin-dependent kinase A links cell cycle reactivation and the acquisition of new cell-type characteristics during reprogramming in the moss Physcomitrella patens, overview. Cell cycle progression is not required for acquisition of protonema cell-type characteristics
-
additional information
-
amino acids in cluster A and B modulate substrate recognition and specificity. Substrate phosphorylation by CDK6 with K-cyclin from Kaposi sarcoma herpesvirus, K-cyclin expression in U2OS cells leads to fragmentation of actin stress fibers
additional information
-
Cdk5 is a proline-directed Ser/Thr protein kinase that is activated by binding to a regulatory subunit p35 or p39, activation mechanism of Cdk5, overview
additional information
-
inhibition of CDK9 with flavopiridol does not result in loss of Bcl2A
additional information
-
Cks1 subunit is involved in SCF-dependent degradation of Cdk inhibitors, while Cks2 subunit is not. Cks1 deficiency is protective against tumor development in genetically engineered mouse models of lymphoma and mammary tumorigenesis
additional information
-
effect of ginsenosides on Alzheimer's disease may be involved with the regulation of activities of cdk5/p25. Enzyme activity measurement by mass spectrometry, UPLC/TQMS method development, usage with liquid chromatographic separation of product, overview
SUBSTRATE
PRODUCT                      
REACTION DIAGRAM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
ATP + a protein
ADP + a phosphoprotein
show the reaction diagram
-
-
-
-
?
ATP + a protein
ADP + a phosphoprotein
show the reaction diagram
-
-
-
-
?
ATP + a protein
ADP + a phosphoprotein
show the reaction diagram
-
-
-
-
?
ATP + a protein
ADP + a phosphoprotein
show the reaction diagram
-
-
-
-
?
ATP + a protein
ADP + a phosphoprotein
show the reaction diagram
-
cdk2-cyclin A phosphorylates e.g. protein substrate p107 and peptide substrate PKTPKKAKKL, requiring a small hydrophobic patch RXL, known as a recruitment peptide
-
-
?
ATP + acidic alpha-syntrophin protein
ADP + acidic alpha-syntrophin phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2, not of cyclin E/CDK2
-
-
?
ATP + ADAQHATPPKKKRKVEDPKDF
ADP + ADAQHAT(P)PPKKKRKVEDPKDF
show the reaction diagram
-
a histone peptide substrate
-
-
?
ATP + ADP-ribosylation factor GTPase activating protein 3 protein
ADP + ADP-ribosylation factor GTPase activating protein 3 phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + AE binding protein 2 protein
ADP + AE binding protein 2 phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + amphiphysin I
ADP + phosphorylated amphiphysin
show the reaction diagram
-
-
-
-
?
ATP + APEX nuclease protein
ADP + APEX nuclease phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + ARAF serine/threonine protein kinase protein
ADP + ARAF serine/threonine protein kinase phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + ATRIP protein
ADP + ATRIP phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + axonal cytoskeleton protein
ADP + phosphorylated axonal cytoskeleton protein
show the reaction diagram
-
-, regulated by integrin alpha1beta1
-
-
?
ATP + B-cell lymphoma protein 2
ADP + phosphorylated B-cell lymphoma protein 2
show the reaction diagram
-
B-cell lymphoma protein 2 is phosphorylated at Ser70, Cdk5-mediated B-cell lymphoma protein 2 phosphorylation is pivotal for the antiapoptotic effect of Bcl-2 and contributes to the maintenance of neuronal survival by Cdk5
-
-
?
ATP + biotin-TVSEESNVLCLSKSPNKHNRLYMKARPFF
ADP + biotin-TVSEESNVLCLSKpSPNKHNRLYMKARPFF
show the reaction diagram
-
-
phosphorylated on Ser595
-
?
ATP + bloom syndrome helicase
ADP + phosphorylated bloom syndrome helicase
show the reaction diagram
-
-, phosphorylation at Ser-714 and Thr-766, both the N- and C-terminal domains are phosphorylated by Cdc2
-
-
?
ATP + Bni4
ADP + phosphorylated Bni4
show the reaction diagram
-
-
-
-
?
ATP + Boi1
ADP + phosphorylated Boi1
show the reaction diagram
-
-
-
-
?
ATP + Boi2
ADP + phosphorylated Boi2
show the reaction diagram
-
-
-
-
?
ATP + BRCA2
ADP + phosphorylated BRCA2
show the reaction diagram
-
phosphorylates at Ser3291, phosphorylation reaches maximal levels in G2/M, phosphorylates at Ser3291, an event that disrupts association with RAD51
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
show the reaction diagram
-
i.e. JNK3, phosphorylation inhibits JNK3 and leads to reduced phosphorylation of c-jun and to reduced apoptosis
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
show the reaction diagram
-
i.e. JNK3, phosphorylation at Thr131
-
-
?
ATP + C-terminal domain of RNA polymerase II
ADP + phosphorylated C-terminal domain of RNA polymerase II
show the reaction diagram
-
-
-
-
?
ATP + C-terminal domain of RNA polymerase II
ADP + phosphorylated C-terminal domain of RNA polymerase II
show the reaction diagram
-
Cdk7 phosphorylates Ser-5 in the heptad repeats of the C-terminal domain of RNA polymerase II, Cdk9 phosphorylates Ser-2 in the C-terminal domain of RNA RNA polymerase II
-
-
?
ATP + CAK
ADP + phosphorylated CAK
show the reaction diagram
-
substrate of cyclin-dependent kinase cdk7
-
-
?
ATP + CALD1 protein
ADP + CALD1 phosphoprotein
show the reaction diagram
-
reccombinant human GST-tagged substrate, with CDK6
-
-
?
ATP + cAMP responsive element binding protein 3-like 2 protein
ADP + cAMP responsive element binding protein 3-like 2 phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2, not of cyclin E/CDK2
-
-
?
ATP + casein
ATP + phosphorylated casein
show the reaction diagram
Q07785
-
-
-
-
ATP + CCAAT/enhancer binding protein gamma protein
ADP + CCAAT/enhancer binding protein gamma phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + cdc2
ADP + phosphorylated cdc2
show the reaction diagram
P24033, P35567
phosphorylation of Thr161
-
-
-
ATP + cdc2 PK
ADP + phosphorylated cdc2 PK
show the reaction diagram
-
substrate of cyclin-dependent kinase activating kinase CAK
-
-
?
ATP + cdc2-like protein
ADP + phosphorylated cdc2-like protein from Caenorhabditis in chimeric complexes including both mitotic and G1/S cyclins
show the reaction diagram
P24033, P35567
from Caenorhabditis in chimeric complexes including both mitotic and G1/S cyclins
-
-
-
ATP + Cdc20
ADP + phosphorylated Cdc20
show the reaction diagram
-
Cdk phosphorylation affects interaction of Cdc20 with Mad2 and the anaphase-promoting complex-cyclosome in HeLa cells
-
-
?
ATP + Cdc20
ADP + phosphorylated Cdc20
show the reaction diagram
-
substrate of Cdk1, rather than of Cdk2
-
-
?
ATP + Cdc20
ADP + phosphorylated Cdc20
show the reaction diagram
-
in vitro substrate of Cdk1 and Cdk2
-
-
?
ATP + Cdc6
ADP + phosphorylated Cdc6
show the reaction diagram
-
-
-
-
?
ATP + Cdc6
ADP + phosphorylated Cdc6
show the reaction diagram
-
-
-
-
?
ATP + Cdk1
ADP + phosphorylated Cdk2
show the reaction diagram
-
Cdk7
-
-
?
ATP + CDK1
ADP + phosphorylated CDK1
show the reaction diagram
-
CDK7 phosphorylates the activation segment or T-loop of CDK1
-
-
?
ATP + cdk2
ADP + phosphorylated cdk2
show the reaction diagram
P24033, P35567
-
-
-
-
ATP + cdk2
ADP + phosphorylated cdk2
show the reaction diagram
-
CDK7 phosphorylates the activation segment or T-loop of CDK2
-
-
?
ATP + Clb6
ADP + phosphorylated Clb6
show the reaction diagram
-
-
-
-
?
ATP + Cln3 protein
ADP + Cln3 phosphoprotein
show the reaction diagram
-
recombinant His-tagged Cln3 protein is phosphorylated by Pho85/Pho80 complexes at S449 and T520. Cdc28 phosphorylates Cln3 to a greater extent than Pho85, probably because it phosphorylates Cln3 at more sites in the PEST region than Pho85
-
-
?
ATP + coiled-coil domain protein 52 protein
ADP + coiled-coil domain protein 52 phosphoprotein
show the reaction diagram
-
substrate of cyclin E/CDK2, not of cyclinA/CDK2
-
-
?
ATP + collapsing response mediator protein
ADP + phosphorylated collapsing response mediator protein
show the reaction diagram
-
-
-
-
?
ATP + CPEB-associated factor Maskin protein
ADP + CPEB-associated factor Maskin phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + Cprk
ADP + phosphorylated Cprk
show the reaction diagram
-
i.e. Cdk5/p35-regulated kinase
-
-
?
ATP + CREB-binding protein
ADP + phosphorylated CREB-binding protein
show the reaction diagram
-
-
-
-
?
ATP + cyclin dependent kinase 2
ADP + phosphorylated cyclin dependent kinase 2
show the reaction diagram
-
cyclin activating kinase CAK phosphorylates Thr160 of cdk2, a prerequisite for cell cycle control
-
-
?
ATP + cyclin H protein
ADP + cyclin H phosphoprotein
show the reaction diagram
-
CDK8
-
-
?
ATP + cyclin-dependent kinase
ADP + phosphorylated cyclin-dependent kinase
show the reaction diagram
-
-
-
-
?
ATP + Dab1 protein
ADP + Dab1 phosphoprotein
show the reaction diagram
-
-, Cdk5-p35 or Cdk5-p39
-
-
?
ATP + dephosphin
ADP + phosphorylated dephosphin
show the reaction diagram
-
-, Cdk5 regulates endocytosis involving dephosphin activity, overview
-
-
?
ATP + diacylglycerol kinase epsilon protein
ADP + diacylglycerol kinase epsilon phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + diphthamide biosynthesis protein 2 isoform a protein
ADP + diphthamide biosynthesis protein 2 isoform a phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + distal-less homeobox 1 isoform 1 protein
ADP + distal-less homeobox 1 isoform 1 phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + DNA polymerase alpha
ADP + phosphorylated DNA polymerase alpha
show the reaction diagram
-
-
-
-
?
ATP + DNA polymerase sigma
ADP + phosphorylated DNA polymerase sigma
show the reaction diagram
-
-
-
-
?
ATP + dopamine
ADP + phosphorylated dopamine
show the reaction diagram
-
phosphorylation by cdk5
-
-
?
ATP + dopamine and cAMP-regulated phosphoprotein
ADP + phosphorylated dopamine and cAMP-regulated phosphoprotein
show the reaction diagram
-
i.e. DARPP-32, phosphorylation by cdk5 at Thr75 and Thr34
-
-
?
ATP + dynamin I
ADP + phosphorylated dynamin
show the reaction diagram
-
-
-
-
?
ATP + E2F1 protein
ADP + E2F1 phosphoprotein
show the reaction diagram
-
CDK8
-
-
?
ATP + early mitotic inhibitor 1 protein
ADP + early mitotic inhibitor 1 phosphoprotein
show the reaction diagram
-
-, i.e. Emi1, is phosphorylated by CDKs in mitotic but not S-phase cell extracts
-
-
?
ATP + ephexin 1
ADP + phosphorylated ephexin 1
show the reaction diagram
-
-
-
-
?
ATP + ErbB2
ADP + phosphorylated ErbB2
show the reaction diagram
-
phosphorylation of the neuregulin receptor by Cdk5 is involved in regulation of neuregulin
-
-
?
ATP + ErbB2
ADP + phosphorylated ErbB2
show the reaction diagram
-
phosphorylation at Thr871
-
-
?
ATP + ErbB3
ADP + phosphorylated ErbB3
show the reaction diagram
-
phosphorylation of the neuregulin receptor by Cdk5 is involved in regulation of neuregulin
-
-
?
ATP + ErbB3
ADP + phosphorylated ErbB3
show the reaction diagram
-
phosphorylation at Ser1120
-
-
?
ATP + Erp1/emi2 protein
ADP + Erp1/emi2 phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + establishment of cohesion-1 homologue 2 protein
ADP + establishment of cohesion-1 homologue 2 phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + estrogen receptor
ADP + phosphorylated estrogen receptor
show the reaction diagram
-
Cdk2 phosphorylation at Ser104 and Ser106
-
-
?
ATP + ETS variant gene-1 protein
ADP + ETS variant gene-1 phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + eukaryotic elongation factor 2
ADP + phosphorylated eukaryotic elongation factor 2
show the reaction diagram
-
phosphorylation on Ser595 by Cdk2, phosphorylation on Ser595 by Cdk2. Substrate mutant S595A is poorly phosphorylated by cyclin A-CDK2
-
-
?
ATP + ezrin
ADP + phosphorylated ezrin
show the reaction diagram
-
phosphorylation by cdk5 at Thr235 in the NH2-terminal region and consequent dissociation of Rho GDP dissociation inhibitor from an ezrin/Rho-GDI complex
-
-
?
ATP + Fin1
ADP + phosphorylated Fin1
show the reaction diagram
-
-
-
-
?
ATP + Fizzy1 protein
ADP + Fizzy1 phosphoprotein
show the reaction diagram
-
substrate of cyclin E/CDK2, not of cyclinA/CDK2
-
-
?
ATP + Fkh2p
ADP + phosphorylated Fkh2p
show the reaction diagram
-
phosphorylation of forkhead transcription factor Fkh2p is part of regulation of cell cycle-specific gene expression, e.g. of the CLB2 cluster, Fkh2p phosphorylation by Cdc28p is regulated by complex formation with Mcm1p and Ndd1p, and phosphorylation, overview, forkhead transcription factor Fkh2p, C-terminally phosphorylation of Fkh2p promotes interaction with the activator Ndd1p, which becomes also phosphorylated, activity with Fkh2p mutants, overview
-
-
?
ATP + glucocorticoid receptor
ADP + dephosphorylated glucocorticoid receptor
show the reaction diagram
-
CDK5 phosphorylates glucocorticoid receptor at multiple serines, including Ser203 and Ser211 of its N-terminal domain, and suppresses the transcriptional activity of this receptor on glucocorticoid-responsive promoters by attenuating attraction of transcriptional cofactors to DNA
-
-
?
ATP + glucocorticoid receptor
ADP + phosphorylated glucocorticoid receptor
show the reaction diagram
-
-
-
-
?
ATP + glycogenin protein
ADP + glycogenin phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1, not of cyclinA/CDK2
-
-
?
ATP + granulin isoform 1 precursor protein
ADP + granulin isoform 1 precursor phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + heat shock transcription factor 1 protein
ADP + heat shock transcription factor 1 phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + Hermes protein
ADP + Hermes phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + HHASPRK
ADP + HHAS(P)PRK
show the reaction diagram
-
-
-
-
?
ATP + HHASPRK
ADP + phosphorylated HHASPRK
show the reaction diagram
-
-
-
-
?
ATP + high-molecular-weight neurofilament
ADP + phosphorylated high-molecular-weight neurofilament
show the reaction diagram
-
-
-
-
-
ATP + histone 1
ADP + phosphorylated histone 1
show the reaction diagram
-
-
-
-
?
ATP + histone 1
ADP + phosphorylated histone 1
show the reaction diagram
-
-
-
-
?
ATP + histone deacetylase 6 protein
ADP + histone deacetylase 6 phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
Q07785
-
-
-
-
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
-
commercial substrate
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
-
preferred substrate of cdk5 associated with p35
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
-
substrate of Cdk-A/cyclin D2
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
-
commercial substrate, Cdk5
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
-
substrate of Cdk-A/cyclin D2 and of proliferating cell nuclear antigen/cyclin D2
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
P21127
substrate of CDK11p110
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
-
substrate of CDKB
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
-
substrate of e.g. of cheimeric K-cyclin/cdk6 and K-cyclin-cyclin D2
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
-
CDK2
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
Mus musculus ICR
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
Arabidopsis thaliana Col-0
-
-
-
-
?
ATP + histone H1
ADP + dephosphorylated hiostone H1
show the reaction diagram
P24033, P35567
-
-
-
-
ATP + histone H1
ADP + phosphorylated steroid histone H1
show the reaction diagram
-
-
-
-
?
ATP + histone H1-derived peptide
ADP + histone H1-derived peptide phosphate
show the reaction diagram
-
-
-
-
?
ATP + histone H3 protein
ADP + histone H3 phosphoprotein
show the reaction diagram
-
CDK8
-
-
?
ATP + histone stem-loop binding protein
ADP + histone stem-loop binding phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + human cytomegalovirus tegument protein pp65
ADP + phosphorylated human cytomegalovirus tegument protein pp65
show the reaction diagram
-
-
-
-
?
ATP + huntingtin
ADP + phosphorylated huntingtin
show the reaction diagram
-
-
-
-
?
ATP + huntingtin
ADP + phosphorylated huntingtin
show the reaction diagram
-
huntingtin is phosphorylated by Cdk5 at Ser1181 and Ser1201
-
-
?
ATP + Kunitz type serine protease inhibitor 2 protein
ADP + Kunitz type serine protease inhibitor 2 phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + lamina-associated protein 2-beta isoform protein
ADP + lamina-associated protein 2-beta isoform phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2, not of cyclin E/CDK2
-
-
?
ATP + LOC222229 protein
ADP + LOC222229 phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + low density lipoprotein receptor adaptor protein 1 protein
ADP + low density lipoprotein receptor adaptor protein 1 phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + MAP/microtubule affinity regulating kinase 3 protein
ADP + MAP/microtubule affinity regulating kinase 3 phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + MAP1B
ADP + phosphorylated MAP1B
show the reaction diagram
-
-
-
-
?
ATP + MAP1B
ADP + phosphorylated MAP1B
show the reaction diagram
-
reaction in growth cones is important for stability of microtubules, type 1 phosphorylation in the mab1E11 recognition site
-
-
?
ATP + MAP2
ADP + phosphorylated MAP2
show the reaction diagram
-
-
-
-
?
ATP + maternal embryonic leucine zipper kinase protein
ADP + maternal embryonic leucine zipper kinase phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + Mcm3
ADP + phosphorylated Mcm3
show the reaction diagram
-
-
-
-
?
ATP + Mcm4
ADP + phosphorylated Mcm4
show the reaction diagram
-
-
-
-
?
ATP + Med13 protein
ADP + Med13 phosphoprotein
show the reaction diagram
-
CDK8
-
-
?
ATP + MEF2
ADP + phosphorylated MEF2
show the reaction diagram
-
-
-
-
?
ATP + MEK1
ADP + phosphorylated MEk1
show the reaction diagram
-
Cdk5 regulates the ERK1/2 pathway through phosphorylation of MEK1, overview
-
-
?
ATP + MEK1
ADP + phosphorylated MEk1
show the reaction diagram
-
phosphorylation at Thr286
-
-
?
ATP + MEP50 protein
ADP + MEP50 phosphoprotein
show the reaction diagram
-
a PRMT5 co-regulatory factor
-
-
?
ATP + MEP50 protein
ADP + MEP50 phosphoprotein
show the reaction diagram
-
a PRMT5 co-regulatory factor, purified recombinant PRMT5/MEP50 produced in Sf9 cells or HeLa cells, phosphorylation of Thr5 and perhaps Ser264 by CDK4
-
-
?
ATP + MGC86234 protein
ADP + MGC86234 phosphoprotein
show the reaction diagram
-
i.e. potassium channel tetramerisation domaincontaining 3, substrate of cyclinA/CDK2, not of cyclin E/CDK2
-
-
?
ATP + microtubule-associated tau
ADP + phosphorylated microtubule-associated tau
show the reaction diagram
-
-
-
-
-
ATP + mini-chromosomemaintenance protein 2
ADP + phosphorylated mini-chromosomemaintenance protein 2
show the reaction diagram
-
-
-
-
?
ATP + mini-chromosomemaintenance protein 3
ADP + phosphorylated mini-chromosomemaintenance protein 3
show the reaction diagram
-
-
-
-
?
ATP + mini-chromosomemaintenance protein 4
ADP + phosphorylated mini-chromosomemaintenance protein 4
show the reaction diagram
-
-
-
-
?
ATP + mini-chromosomemaintenance protein 5
ADP + phosphorylated mini-chromosomemaintenance protein 5
show the reaction diagram
-
-
-
-
?
ATP + mini-chromosomemaintenance protein 6
ADP + phosphorylated mini-chromosomemaintenance protein 6
show the reaction diagram
-
-
-
-
?
ATP + mini-chromosomemaintenance protein 7
ADP + phosphorylated mini-chromosomemaintenance protein 7
show the reaction diagram
-
-
-
-
?
ATP + minor histocompatibility antigen HA-1 protein
ADP + minor histocompatibility antigen HA-1 phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + Munc-18
ADP + phosphorylated Munc-18
show the reaction diagram
-
-, involved in regulation of exocytosis involving SNARE proteins, Munc-18 is required for mediating secretory responsesoverview
-
-
?
ATP + neuregulin receptor ErbB2
ADP + phosphorylated neuregulin receptor ErbB2
show the reaction diagram
-
phosphorylation at Ser1176 by Cdk5, phosphorylation at Ser1176 in the sequence RPKTLSPGKN by Cdk5
-
-
?
ATP + neuregulin receptor ErbB3
ADP + phosphorylated neuregulin receptor ErbB3
show the reaction diagram
-
phosphorylation at Thr871 and Ser1120 by Cdk5
-
-
?
ATP + neuregulin receptor ErbB3
ADP + phosphorylated neuregulin receptor ErbB3
show the reaction diagram
-
phosphorylation at Thr871 and Ser1120 in the consensus sequence RSRSPR by Cdk5, Cdk5 associates with Erb3 in vivo, phosphorylation at Thr871 in the sequence AKTPIKWAL and Ser1120 in the consensus sequence RSRSPR by Cdk5, weak phosphorylation of Ser1204 in the proline-rich sequence RRGSPPRPPR
-
-
?
ATP + neurofilament heavy chain
ADP + phosphorylated neurofilament heavy chain
show the reaction diagram
-
-
-
-
?
ATP + neuronal cytoskeletal protein NF-H
ADP + phosphorylated neuronal cytoskeletal protein NF-H
show the reaction diagram
P51166
-
-
-
-
ATP + neuronal cytoskeletal protein tau
ADP + phosphorylated neuronal cytoskeletal protein tau
show the reaction diagram
P51166
-
-
-
-
ATP + neuronal cytoskeletal proteins NF-M
ADP + phosphorylated neuronal cytoskeletal protein NF-M
show the reaction diagram
P51166
-
-
-
-
ATP + NF-H
ADP + phosphorylated NF-H
show the reaction diagram
-
neurofilament protein that correlates neurit outgrowth, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
show the reaction diagram
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
show the reaction diagram
-
neurofilament protein, phosphorylation at the KSP repeats
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
show the reaction diagram
-
neurofilament protein, phosphorylation at the KSP repeats, hyperactivated Cdk5-p25
-
-
?
ATP + NF-H peptide
ADP + phosphorylated NF-H peptide
show the reaction diagram
-
-
-
-
?
ATP + NF-H peptide
ADP + phosphorylated NF-H peptide
show the reaction diagram
-
i.e. RREAKSPAKAKSPAKE
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
show the reaction diagram
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
show the reaction diagram
-
neurofilament protein, phosphorylation at the KSP repeats
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
show the reaction diagram
-
neurofilament protein, phosphorylation at the KSP repeats, hyperactivated Cdk5-p25
-
-
?
ATP + NR1 receptor
ADP + phosphorylated NR1 receptor
show the reaction diagram
-
-, involved in synaptic transmission, overview
-
-
?
ATP + NR2 receptor
ADP + phosphorylated NR2 receptor
show the reaction diagram
-
involved in synaptic transmission, phosphorylation of Ser1232 on the A subunit upregulates NMCAR activity, overview, with phosphorylation sites on both, A and B subunits, e.g. Ser1232 on the A subunit
-
-
?
ATP + Orc2
ADP + phosphorylated Orc2
show the reaction diagram
-
-
-
-
?
ATP + Orc6
ADP + phosphorylated Orc6
show the reaction diagram
-
-
-
-
?
ATP + origin recognition complex 1
ADP + phosphorylated origin recognition complex 1
show the reaction diagram
-
-
-
-
?
ATP + origin recognition complex 2
ADP + phosphorylated origin recognition complex 2
show the reaction diagram
-
-
-
-
?
ATP + origin recognition complex 3
ADP + phosphorylated origin recognition complex 3
show the reaction diagram
-
-
-
-
?
ATP + origin recognition complex 4
ADP + phosphorylated origin recognition complex 4
show the reaction diagram
-
-
-
-
?
ATP + origin recognition complex 5
ADP + phosphorylated origin recognition complex 5
show the reaction diagram
-
-
-
-
?
ATP + origin recognition complex 6
ADP + phosphorylated origin recognition complex 6
show the reaction diagram
-
-
-
-
?
ATP + p35 protein
ADP + p35 phosphoprotein
show the reaction diagram
-
a nuclear transcription factor, Cdk5-p25 phosphorylates p53 on Ser15, Ser33, and Ser44
-
-
?
ATP + Pak1
ADP + phosphorylated Pak1
show the reaction diagram
-
-
-
-
?
ATP + palmitoylated membrane protein 1 protein
ADP + palmitoylated membrane protein 1 phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + parkin
ADP + phosphorylated parkin
show the reaction diagram
-
-
-
-
?
ATP + parkin
ADP + phosphorylated parkin
show the reaction diagram
-
Ser-131 located at the linker region of parkin is the major Cdk5 phosphorylation site, phosphorylation by Cdk5 decreases the auto-ubiquitylation of parkin, parkin S131A mutant has 40% lower phosphorylation levels in vivo than wild-type parkin, Ser-131 located at the linker region of parkin is the major Cdk5 phosphorylation site, phosphorylation by Cdk5 decreases the auto-ubiquitylation of parkin
-
-
?
ATP + parkin
ADP + phosphorylated parkin
show the reaction diagram
-
parkin has four putative Cdk5 phosphorylation sites according to the motif (S/T)PX(K/R)
-
-
?
ATP + PASCIN protein
ADP + PASCIN phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + Pho81
ADP + phosphorylated Pho81
show the reaction diagram
-
-
phosphorylated Pho81 is an inhibitor for Pho85
-
?
ATP + phosphatidylinositol-4-phosphate 5-kinase type IIba protein
ADP + phosphatidylinositol-4-phosphate 5-kinase type IIba phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2, not of cyclin E/CDK2
-
-
?
ATP + PIF1 protein
ADP + PIF1 phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + PKTPKKAKKL
ADP + PKpTPKKAKKL
show the reaction diagram
-
-
-
-
?
ATP + PKTPKKAKKL
ADP + PKpTPKKAKKL
show the reaction diagram
-
GST-tagged recombinant peptide substrate
-
-
?
ATP + pocket protein p107
ADP + phosphorylated pocket protein 107
show the reaction diagram
-
hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + pocket protein p107
ADP + phosphorylated pocket protein 107
show the reaction diagram
-
hyperphosphorylation by CDK/cyclin
-
-
?
ATP + pocket protein p130
ADP + phosphorylated pocket protein 130
show the reaction diagram
-
hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + pocket protein p130
ADP + phosphorylated pocket protein 130
show the reaction diagram
-
hyperphosphorylation by CDK/cyclin
-
-
?
ATP + POM21 protein
ADP + POM21 phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + pre-B-cell leukemia transcription factor 1 protein
ADP + pre-B-cell leukemia transcription factor 1 phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2, not of cyclin B/CDK1
-
-
?
ATP + pre-synaptic P/Q-type voltage-dependent calcium channel
ADP + phosphorylated pre-synaptic P/Q-type voltage-dependent calcium channel
show the reaction diagram
-
-
-
-
?
ATP + progesterone receptor
ADP + phosphorylated progesterone receptor
show the reaction diagram
-
cyclin-dependent kinase activity is required for progesterone receptor PR function, the phosphorylation of the receptor protein has little effect, but cyclin A/Cdk2 acts as a progesterone receptor coactivator via stimulation of PR transcription, Cdk2-cyclin A is PR-dependently recruited to the PR promoter binding to cyclin A, mechanism involving SCR-1 and regulation, overview, Cdk2-cyclin A
-
-
?
ATP + progesterone receptor
ADP + phosphorylated progesterone receptor
show the reaction diagram
-
cyclin A2/Cdk2 phosphorylates progesterone receptor in vivo at Ser20 and Ser676, Ser162, Ser190 and Ser400, cyclin A2/Cdk2 phosphorylates progesterone receptor in vitro at Ser25, Ser162, Ser190, Ser213, Ser400, Thr 430, Ser554 and Ser676
-
-
?
ATP + promyelocytic leukemia zinc finger
ADP + phosphorylated promyelocytic leukemia zinc finger
show the reaction diagram
-
can also be phosphorylated by CDK1 albeit in a less efficient fashion than by CDK2
-
-
?
ATP + protein
ADP + phosphoprotein
show the reaction diagram
-
-
-
-
-
ATP + protein
ADP + phosphoprotein
show the reaction diagram
-
-
-
-
-
ATP + protein
ADP + phosphoprotein
show the reaction diagram
Q04735, Q04899
serine/threonine-specific protein kinase
-
-
-
ATP + protein
ADP + phosphoprotein
show the reaction diagram
Q15131
the enzyme is likely to be involved in regulating the cell cycle and therefore may have a role in oncogenesis
-
-
-
ATP + protein
ADP + phosphoprotein
show the reaction diagram
-
proline-directed kinase
-
-
-
ATP + protein
ADP + phosphoprotein
show the reaction diagram
Q02399
proline-directed kinase
-
-
-
ATP + protein
ADP + phosphoprotein
show the reaction diagram
P30285, Q03147
receptor protein tyrosine kinase
-
-
-
ATP + protein
ADP + phosphoprotein
show the reaction diagram
O35831, O35832
Ser/Thr kinase
-
-
-
ATP + protein
ADP + phosphoprotein
show the reaction diagram
-
Ser/Thr kinase
-
-
-
ATP + protein
ADP + phosphoprotein
show the reaction diagram
Emericella nidulans
-
NIMA is a cell cycle regulated protein kinase required, in addition to p34cdc2/cyclin B, for initiation of mitosis. NIMA accumulates when cells are arrested in G2 and is degraded as cells traverse mitosis. NIMA degradation during mitosis is required for correct mitotic progression in Aspergillus nidulans
-
-
?
ATP + protein tau
ADP + protein tau phosphate
show the reaction diagram
-
-
-
-
?
ATP + protein tau
ADP + protein tau phosphate
show the reaction diagram
-
-
-
-
?
ATP + PSD-95
ADP + phosphorylated PSD-95
show the reaction diagram
-
-
-
-
?
ATP + Rad9 protein
ADP + Rad9 phosphoprotein
show the reaction diagram
-
a DNA damage response mediator, a DNA damage response mediator, phosphorylaation at Thr125 and Thr143
-
-
?
ATP + RasGRF1
ADP + phosphorylated RasGRF1
show the reaction diagram
-
-
-
-
?
ATP + RasGRF2
ADP + phosphorylated RasGRF2
show the reaction diagram
-
-
-
-
?
ATP + Rb peptide
ADP + Rb phosphopeptide
show the reaction diagram
-
from retinoblastoma-associated protein
-
-
?
ATP + replication factor C
ADP + phosphorylated replication factor C
show the reaction diagram
-
-
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
show the reaction diagram
-
-
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
show the reaction diagram
-
-
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
show the reaction diagram
-
i.e. Rb protein
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
show the reaction diagram
-
i.e. Rb protein
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
show the reaction diagram
-
i.e. Rb protein, hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
show the reaction diagram
-
phosphorylation by CDK4/cyclin D at one site, or by CDK2/cyclin E or A at multiple sites in the cell cycle G1 phase
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
show the reaction diagram
-
i.e. Rb protein, hyperphosphorylation by CDK/cyclin
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
show the reaction diagram
-
i.e. Rb protein, phosphorylation by CDK4/cyclin D
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
show the reaction diagram
-
i.e. Rb protein, phosphorylation by CDK4/cyclin D at one site, or by CDK2/cyclin E or A at multiple sites
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
show the reaction diagram
-
i.e. Rb protein, recombinant GST-tagged substrate, substrate of e.g. of chimeric K-cyclin/cdk6 and K-cyclin-cyclin D2
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
show the reaction diagram
P97377
the phosphorylation site is at Ser795
-
-
?
ATP + retinoblastoma protein
ADP + retinoblastoma phosphoprotein
show the reaction diagram
-
a tumor suppressor protein, a tumor suppressor protein, phosphorylated by Cdk5-p25
-
-
?
ATP + retinoblastoma-related protein
ADP + phosphorylated retinoblastoma-related protein
show the reaction diagram
-
i.e. RBR, substrate of Cdk-A/cyclin D2, i.e. RBR, substrate of Cdk-A/cyclin D2 and of proliferating cell nuclear antigen/cyclin D2
-
-
?
ATP + Rga2
ADP + phosphorylated Rga2
show the reaction diagram
-
-
-
-
?
ATP + RhoGEF Tus1p
ADP + phosphorylated RhoGEF Tus1p
show the reaction diagram
Saccharomyces cerevisiae, Saccharomyces cerevisiae YOC3388
-
-
-
-
?
ATP + RNA polymerase 1 protein
ADP + RNA polymerase 1 phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + RNA polymerase II
ADP + phosphorylated RNA polymerase II
show the reaction diagram
-
-
-
-
?
ATP + RNA polymerase II
ADP + phosphorylated RNA polymerase II
show the reaction diagram
-
-
-
-
-
ATP + RNA polymerase II
ADP + phosphorylated RNA polymerase II
show the reaction diagram
Q5JK68, Q6I5Y0
-
-
-
?
ATP + RNA polymerase II
ADP + phosphorylated RNA polymerase II
show the reaction diagram
Q8W4P1
phosphorylate the C-terminal domain of RNA polymerase II
-
-
?
ATP + RNA polymerase II
ADP + phosphorylated RNA polymerase II
show the reaction diagram
-
CDK9 phosphorylates the carboxy-terminal domain of the largest subunit (RPB1) of RNA polymerase II
-
-
?
ATP + RNA polymerase II
ADP + phosphorylated RNA polymerase II
show the reaction diagram
-
CDK7 and CDK8 phosphorylate the C-terminal domain of RNA Pol II
-
-
?
ATP + RNA polymerase II C-terminal domain
ADP + phosphorylated RNA polymerase II C-terminal domain
show the reaction diagram
-
phosphorylation by Cdk7 and Cdk9, phosphorylation at serine residues 2 and 5
-
-
?
ATP + RNA polymerase II C-terminal domain
ADP + phosphorylated RNA polymerase II C-terminal domain
show the reaction diagram
-
reccombinant GST-tagged substrate
-
-
?
ATP + RNA polymerase II C-terminal domain protein
ADP + RNA polymerase II C-terminal domain phosphoprotein
show the reaction diagram
-
-
-
-
?
ATP + RNA polymerase II carboxy-terminal domain
ADP + phosphorylated RNA polymerase II carboxy-terminal domain
show the reaction diagram
-
CDK8
-
-
?
ATP + RNA polymerase II largest subunit
ADP + phosphorylated RNA polymerase II largest subunit
show the reaction diagram
Q03957
specifically hyperphosphorylates the carboxyl-terminal
-
-
-
ATP + RXL motif-containing peptide
ADP + RXL motif-containing phosphopeptide
show the reaction diagram
-
peptide sequence corresponding to amino acids 866-880 of RNA polymerase II C-terminal domain. Substrate phosphorylation by CDK6 with K-cyclin from Kaposi sarcoma herpesvirus, but addition of this peptide significantly reduces substrate phosphorylation by cyclin E-CDK2 and cyclin D2-CDK6
-
-
?
ATP + SCR-1
ADP + phosphorylated SCR-1
show the reaction diagram
-
Cdk2-cyclin A, phosphorylation at Lys5 regulates SCR-1 interaction with the progesterone receptor, Cdk2-cyclin A, phosphorylation at Lys5
-
-
?
ATP + SEC14-like 1 isoform a protein
ADP + SEC14-like 1 isoform a phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + semaphorin 6D protein
ADP + semaphorin 6D phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + Sept5 protein
ADP + phosphorylated Sept5 protein
show the reaction diagram
-
Sept5 protein is phosphorylated at Ser17
-
-
?
ATP + septine 5
ADP + phosphorylated septine 5
show the reaction diagram
-
Ser327 is the major phosphorylation site for Cdk5 in presence of activator p35
-
-
?
ATP + Sic1
ADP + phosphorylated Sic1
show the reaction diagram
-
-, Glc8 function is dependent on phosphorylation at Thr-118, which is phosphorylated by Pho85 in conjunction with cyclins Pcl6 and Pcl7, and possibly Pcl8 and Pcl10
-
-
?
ATP + similar to bicaudal C homologue 1 protein
ADP + similar to bicaudal C homologue 1 phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + similar to peroxisomal biogenesis factor 5 protein
ADP + similar to peroxisomal biogenesis factor 5 phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + similar to Trigger of mitotic entry 1 protein
ADP + similar to Trigger of mitotic entry 1 phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + similar to Zinc finger protein 516 protein
ADP + similar to Zinc finger protein 516 phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + SIRT2
ADP + phosphorylated SIRT2
show the reaction diagram
-
-
-
-
?
ATP + SMAD protein
ADP + SMAD phosphoprotein
show the reaction diagram
-
CDK8
-
-
?
ATP + SMARCD2/BAF60:SWI/SNF-related matrix-associated actin-dependent regulator of chromatin d2 protein
ADP + SMARCD2/BAF60:SWI/SNF-related matrix-associated actin-dependent regulator of chromatin d2 phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + SmcX-Jumonji/ARID domain-containing protein 1C protein
ADP + SmcX-Jumonji/ARID domain-containing protein 1C phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + STAT3
ADP + phosphorylated STAT3
show the reaction diagram
-
-
-
-
?
ATP + STAT3
ADP + phosphorylated STAT3
show the reaction diagram
-
specific phosphorylation at Ser727 by CDK5-p35, CDK5 is involved in regulation of the signal transducer and transcription activator STAT3 in brain and muscle, specific phosphorylation at Ser727 by CDK5-p35
-
-
?
ATP + STAT3
ADP + phosphorylated STAT3
show the reaction diagram
-
substrate of CDK5
-
-
?
ATP + STAT3 protein
ADP + STAT3 phosphoprotein
show the reaction diagram
-
Cdk5 phosphorylates at Ser727
-
-
?
ATP + steroid receptor coactivator-1
ADP + phosphorylated steroid receptor coactivator-1
show the reaction diagram
-
-
-
-
?
ATP + steroidogenic factor 1
ADP + phosphorylated steroidogenic factor 1
show the reaction diagram
-
also known as Ad4BP, systematic name NR5A1, the phosphorylation site is at Ser203
-
-
?
ATP + striatin protein
ADP + striatin phosphoprotein
show the reaction diagram
-
substrate of cyclin E/CDK2, not of cyclinA/CDK2
-
-
?
ATP + Swi5
ADP + phosphorylated Swi5
show the reaction diagram
-
-
-
-
?
ATP + Swi6
ADP + phosphorylated Swi6
show the reaction diagram
-
substrate of cdc28p
-
-
?
ATP + synaptojanin I
ADP + phosphorylated synaptojanin I
show the reaction diagram
-
-
-
-
?
ATP + syntaxin-1
ADP + phosphorylated syntaxin-1
show the reaction diagram
-
-
-
-
?
ATP + syntaxin-1
ADP + phosphorylated syntaxin-1
show the reaction diagram
-
-
-
-
?
ATP + T-cell protein tyrosine phosphatase
ADP + phosphorylated T-cell protein tyrosine phosphatase
show the reaction diagram
-
phosphorylation of the two splicing varaints TC45 and TC48 at Ser304 in a cell cycle-dependent manner, optimally in mitosis, overview, phosphorylation of the two splicing varaints TC45 and TC48 at Ser304 in the sequence AFDHS(P), no activity with substrate mutant S304A
-
-
?
ATP + TATA box-binding protein-associated factor 2F protein
ADP + TATA box-binding protein-associated factor 2F phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1, not of cyclinA/CDK2
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
show the reaction diagram
-
-
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
show the reaction diagram
-
-
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
show the reaction diagram
-
-
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
show the reaction diagram
-
-
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
show the reaction diagram
-
cdk5 substrate in brain, Cdk5-p25 or Cdk5-p35
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
show the reaction diagram
-
hyperactivated Cdk5-p25
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
show the reaction diagram
-
Cdk5 phosphorylates at S202, S235, and S404, phosphorylation at S235 primes it for phosphorylation of T231 by GSK3beta, phosphorylating tau protein at S404 primes tau protein for a sequential phosphorylation of S400 and S396 by GSK3beta
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
show the reaction diagram
-
phosphorylation at Ser235 by cdk5 primes phosphorylation at Thr231 by GSK-3alpha/beta. Tau protein isoforms with the two N-terminal inserts s4L and s3L are more favorable substrates than tau protein isoforms without the inserts. Thr231 is phosphorylated ca. 50% more in free tau protein than in microtubule-bound one
-
-
?
ATP + Tau protein
ADP + Tau phosphoprotein
show the reaction diagram
-
Cdk5-p25 has a stronger Tau-phosphorylating activity than Cdk5-p35 in neurons, Cdk5-p25 or Cdk5-p35 or Cdk5-p39
-
-
?
ATP + telomeric repeat binding factor 2 protein
ADP + telomeric repeat binding factor 2 phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + Tipin protein
ADP + Tipin phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + tumor suppressor Rb
ADP + phosphorylated tumor suppressor Rb
show the reaction diagram
-
-
-
-
?
ATP + v-raf murine sarcoma viral oncogene homolog B1 protein
ADP + v-raf murine sarcoma viraloncogene homolog B1 phosphoprotein
show the reaction diagram
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + Vac17
ADP + phosphorylated Vac17
show the reaction diagram
-
-
-
-
?
ATP + Varicella-Zoster virus IE63 protein
ADP + phosphorylated Varicella-Zoster virus IE63 protein
show the reaction diagram
-
phosphorylation at Ser224 by CDK1 in vivo is required for correct localization of the virus protein, e.g. in the host cytoplasm during latency, S224A mutation leads to inhibition of phosphorylation and exclusive localization of IE63 protein in the nucleus, recombinant wild-type and mutant IE63 proteins expressed in Vero cells, phosphorylation at Ser224 of wild-type and mutants T222E and T222A by CDK1 and CDK5, but not by CDK2, CDK7, and CDK9 in vitro, mutant S224A is no substrate
-
-
?
ATP + VGCC
ADP + phosphorylated NR1 receptor
show the reaction diagram
-
a voltage-dependent calcium channel, phosphorylation within the intracellular loop of the channel inhibiting interaction with SNARE proteins, SNAP-25, and synaptotagmin I required for neurotransmitter release, overview, a voltage-dependent calcium channel, phosphorylation within the intracellular loop of the channel
-
-
?
ATP + WAVE1
ADP + phosphorylated WAVE1
show the reaction diagram
-
-
-
-
?
ATP + Wee1A
ADP + phosphorylated Wee1A
show the reaction diagram
-
phosphorylation at S123, S53, and S121 promotes binding of Wee1A by beta-TrCP, the beta-transducin repeat-containing protein, which is the substrate recognition component of the ubiquitin ligase, leading to proteasomal degradation of Wee1A, overview, phosphorylation at S123, S53, and S121
-
-
?
ATP + Xenopus laevis protein associated with PRK1 protein
ADP + Xenopus laevis protein associated with PRK1 phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2, not of cyclin E/CDK2
-
-
?
ATP + zinc finger protein 46 protein
ADP + zinc finger protein 46 phosphoprotein
show the reaction diagram
-
substrate of cyclinA/CDK2, not of cyclin E/CDK2
-
-
?
ATP + [elongation factor 2]
ADP + [elongation factor 2]phosphate
show the reaction diagram
-
the enzyme phosphorylates Ser595. Ser595 phosphorylation varies during the cell cycle and is required for efficient Thr56 phosphorylation (by elongation factor 2 kinase) in vivo, the enzyme phosphorylates Ser595
-
-
?
ATP + [tau protein]
ADP + [O-phospho-tau protein]
show the reaction diagram
-
substrate of CDK5 in the central nervous system, see also EC 2.7.11.26, tau hyperphosphorylation is involved in neurodegeneration and ALzheimer's disease, tau protein phosphorylation by CDK5 is involved in apoptosis in cortical cells, substrate of CDK5 in the central nervous system, see also EC 2.7.11.26, phosphorylation at the PHF-1 epitope, not the Tau-1 epitope, of tau protein by CDK5-p25
-
-
?
ATP + [tau protein]
ADP + O-phospho-[tau-protein]
show the reaction diagram
-
Cdk5-p25 or Cdk5-p35, see also EC 2.7.11.26
-
-
?
ATP + [tau protein]
ADP + O-phospho-[tau-protein]
show the reaction diagram
-
Cdk5-p25 or Cdk5-p35, see also EC 2.7.11.26, phosphorylation at Ser202 and Thr205
-
-
?
ATP + [tau-protein]
ADP + O-phospho -[tau-protein]
show the reaction diagram
-
cdk5 substrate in brain, cdk5 associated with p39, tau is a microtubule-associated and developmentally regulated protein involved in axonal development in neurons, tau phosphorylation by cyclin-dependent kinase 5/p39 during brain development reduces its affinity for microtubules, reaction of EC 2.7.11.26, preferred substrate of cdk5 associated with p39, recombinant bacterially expressed human tau protein as substrate, phosphorylation at Ser202 and Thr205, reaction of EC 2.7.11.26
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
show the reaction diagram
-
-
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
show the reaction diagram
-
activity in organisms with mutated APP and tau, not in wild-type, overview
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
show the reaction diagram
-
cdk5 associated with p25, cdk5 substrate in brain
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
show the reaction diagram
-
hyperphosphorylation of tau by CDK5 is involved in apoptosis and neurodegeneration in Alzheimer's disease, overview
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
show the reaction diagram
-
tau is microtubule-associated, phopshorylation at T231 by CDK5 causes its release into the cytoplasm
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
show the reaction diagram
-
cdk5 associated with p25, recombinant bacterially expressed human tau protein as substrate, phosphorylation of the AT8 and AT180 epitopes, and at T231 of the Alzheimer's mitotic epitope TG-3
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
show the reaction diagram
-
phosphorylation at T231, no activity with tau mutant T231A
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
show the reaction diagram
-
phosphorylation of the PHF-1 epitope at Ser396 and Ser404 by CDK5
-
-
?
additional information
?
-
-, Q01917
-
-
-
-
additional information
?
-
O76039
the gene coding for the enzyme is a candidate for the following disorders: Nance-Horan syndrome, oral-facial-digital syndrome type 1, and nonsyndromic sensorineural deafness
-
-
-
additional information
?
-
-
enzyme is required for initiation of meiosis and sporulation
-
-
-
additional information
?
-
-
enzyme may play a role in the regulation of plant growth and development
-
-
-
additional information
?
-
P39951
enzyme is required for mitosis
-
-
-
additional information
?
-
-
CDK4 amplification might contribute to oncogenesis
-
-
-
additional information
?
-
-
the cdc2 protein kinase plays a role in transcriptional regulation
-
-
-
additional information
?
-
-
mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16INK4a
-
-
-
additional information
?
-
P50750
CDK9 is the catalytic subunit of a general RNA polymerase II elongation factor termed p-TEFb which is targeted by the human immunodeficiency virus Tat protein to activate elongation of the integrated proviral genome
-
-
-
additional information
?
-
-
CDK9 is the catalytic subunit of a general RNA polymerase II elongation factor termed p-TEFb which is targeted by the human immunodeficiency virus Tat protein to activate elongation of the integrated proviral genome
-
-
-
additional information
?
-
-
enzyme is required for M phase in meiotic and mitotic cell divisions, but not for S phase
-
-
-
additional information
?
-
P34117
enzyme is involved in Dictyostelium differentiation rather than growth
-
-
-
additional information
?
-
Q05006
control point in cell cycle
-
-
-
additional information
?
-
Q9W739, -
the enzyme is a component of maturation-promoting factor
-
-
-
additional information
?
-
-
proper regulation of p58 protein kinase is essential for normal cell cycle progression in these cells
-
-
-
additional information
?
-
-
PISSLRE could be involved in processes distinct from cell proliferation
-
-
-
additional information
?
-
-
negative regulatory factors of the PHO system
-
-
-
additional information
?
-
-
enzyme plays a central role in control of the mitotic cell cycle
-
-
-
additional information
?
-
P49336
human K35-cyclin C might be functionally associated with the mammalian transcription apparatus, perhaps involved in relaying growth-regulatory signals
-
-
-
additional information
?
-
-
enzyme is required both for entry into S phase and mitosis
-
-
-
additional information
?
-
-
enzyme is required for both the G1-S and G2-M transitions during mitotic growth, and also for the second meiotic nuclear division
-
-
-
additional information
?
-
Q04859
potential function in sensory cells
-
-
-
additional information
?
-
-
the enzyme is required during both G1 and G2 phases of the cell division cycle
-
-
-
additional information
?
-
P24788
enzyme may have a critical function during normal embryonic development and continues to be expressed in differentiated adult tissues
-
-
-
additional information
?
-
-
key component of the eukaryotic cell cycle, which is required for G1 to S-phase transition and for entry into mitosis
-
-
-
additional information
?
-
P30285, Q03147
enzyme is involved in signal transduction process of pattern formation in the hindbrain
-
-
-
additional information
?
-
-
Kin28 may be a cyclin dependent kinase which is required for cell proliferation
-
-
-
additional information
?
-
P32581
enzyme is required for induction of meiosis
-
-
-
additional information
?
-
P20793
enzyme plays an important role in spermatogenesis
-
-
-
additional information
?
-
P20794
enzyme plays an important role in spermatogenesis
-
-
-
additional information
?
-
-
TFIIH is a multisubunit complex, containing ATPase, helicases, and kinase subunit of TFIIH. In mitosis the CDK7 subunit of TFIIH and the largest subunit of RNAPII become hyperphosphorylated. MPF-induced phosphorylation of CDK7 results in inhibition of the TFIIH-associated kinase and transcription activities
-
-
-
additional information
?
-
P38973, P54665, P54666
enzyme may be involved in controlling aspects of the cell cycle which are linked to the differentiation of the parasite during its complex life cycle
-
-
-
additional information
?
-
-
csk1 may encode a protein kinase physically associated with mcs2 or alternatively may function as an upstream activator of the mcs2-associated kinase
-
-
-
additional information
?
-
-
enzyme is involved in negative regulation of meiotic maturation of Xenopus oocytes
-
-
-
additional information
?
-
Q63699
Cdk2 protein might be required for entry into the S phase of the cell cycle in FRTL-Tc cells
-
-
-
additional information
?
-
-
CDK4 gene is a melanoma-predisposing gene
-
-
-
additional information
?
-
P38973, P54665, P54666
enzyme is involved in controlling aspects of the cell cycle which are linked to the differentiation of the parasite during its complex life cycle
-
-
-
additional information
?
-
P50613
cdk7 is a subunit of the transcription/DNA repair factor TFIIH, cdk7 may phosphorylate the carboxy-terminal domain of RNA pol II in the absence of promoter opening
-
-
-
additional information
?
-
-
can properly regulate the cell cycle
-
-
-
additional information
?
-
-
abnormal phosphorylation of tau in dividing cells leads to its accumulation in the cytosol as microtubule-free form, Cdk5 is involved in neurodegenerative mechanisms
-
-
-
additional information
?
-
-
CDK5-dependent clustering of endoplasmic reticulum ER and mitochondria during ceramide-mediated neuronal death: neurotoxic calcium transfer from ER to mitochondria is regulated by cyclin-dependent kinase 5-dependent phosphorylation of tau, inhibition of the process leads to cell death
-
-
-
additional information
?
-
-
naturally occurring V717I mutation of the amyloid precursor protein APP in a CT100 fragment of mutants leads to augmented age-dependent tau phosphorylation, followed by increased activation status of mitogen-activated protein kinase family members, e.g. ERK1/2, p38, and c-Jun NH2-terminal kinase, compared to the wild-type organism, naturally occurring V337M mutation of tau protein of mutants leads to age-dependent memory deficits
-
-
-
additional information
?
-
-
naturally occurring V717I mutation of the amyloid precursor protein APP in a CT100 fragment of organisms with Alzheimer's disease leads to augmented age-dependent tau phosphorylation, followed by increased activation status of mitogen-activated protein kinase family members, e.g. ERK1/2, p38, and c-Jun NH2-terminal kinase, compared to the wild-type organism, naturally occurring V337M mutation of tau protein of patients suffering from Alzheimer's disease leads to age-dependent memory deficits
-
-
-
additional information
?
-
-
regulation mechanisms, overview
-
-
-
additional information
?
-
-
cdk5 catalyzes tau phosphorylation in brain, but cyclin-dependent phosphorylation of other proteins, EC 2.7.11.22, in different tissues
-
-
-
additional information
?
-
-
poor activity on free amino acids, consensus sequence of cdk2 is S/TP-XR/K
-
-
-
additional information
?
-
-
the enzyme depends on basic residues for substrate recognition, autoregulation by a pseudosubstrate mechanism, overview
-
-
-
additional information
?
-
-
CDK is involved in control of cell differentiation and organogenesis
-
-
-
additional information
?
-
-
Cdk-A/cyclin D2 is involved in DNA replication progress and cell proliferation
-
-
-
additional information
?
-
-
CDK-cyclins and CDK inhibitory proteins are involved in the cell cycle regulation and of vascular cell proliferation and migration, as well as in the control of neointimal thickening, modeling, overview
-
-
-
additional information
?
-
-
Cdk1/cyclin B is induced in cells with dysregulated cell cycle, e.g. after infection with the human cytomegalovirus, regulation mechanisms, overview
-
-
-
additional information
?
-
P21127
CDK11p110 is involved in transcription and RNA processing
-
-
-
additional information
?
-
-
CDK11p58 interacts with the histone acetyltransferase HBO1 in vitro and in vivo, CDK11p58 acts as a regulator of HBO1 activity in eukaryotic transcription
-
-
-
additional information
?
-
-
CDK4 governs cell cycle progression through the G1 phase, CDK2 is involved in all cell cycle phases, overview
-
-
-
additional information
?
-
-
Cdk5 is crucial for stability of axons and growth cones in retina, overview
-
-
-
additional information
?
-
-
Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins
-
-
-
additional information
?
-
-
Cdk5 regulates Akt activation and cell survival through the neuregulin-mediated PI 3-kinase signaling pathway, null mutants show lower phosphatidylinositol 3-kinase activity, Cdk5-p35 mediates neuroprotection
-
-
-
additional information
?
-
-
Cdk5 regulation, overview, Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins, and is critical for neuronal survival, deregulation of Cdk5 occurs in neurodegeneration
-
-
-
additional information
?
-
-
Cdk5 regulation, overview, Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins, deregulation of Cdk5 occurs in neurodegeneration
-
-
-
additional information
?
-
-
Cdk5 regulation, overview, Cdk5 regulates endocytosis through association with amphiphysin and dynamin, Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins, deregulation of Cdk5 occurs in neurodegeneration
-
-
-
additional information
?
-
-
Cdk5-p35 is negatively regulated by interaction with membranes in brain and liver, mechanism
-
-
-
additional information
?
-
-
CDK6/cyclin D1 enhances the transition of cells through the G1 phase of the cell cycle, CDK6 without bound cyclin D1 associates with the androgen receptor AR and enhances, independently of its kinase activity, its transcriptional activity in presence of dihydrotestosterone in prostate cancer cells, this stimulation is highly exaggerated with AR mutant T877A found in prostate cancer, thus CDK6 is probably important for prostate cancer development, CDK6 is no essential for stimulation of AR, overview
-
-
-
additional information
?
-
-, Q8GVD7, Q8GVD8
CDKA1 is involved in cell cycle regulation and dormancy
-
-
-
additional information
?
-
-
CDKB and CDKA are regulated through phosphorylation and cyclins A and B during the cll cycle, regulation overview
-
-
-
additional information
?
-
-, Q8GVD7, Q8GVD8
CDKB1 is involved in cell cycle regulation and dormancy
-
-
-
additional information
?
-
-
Cdks are cell cycle regulating enzymes, Cdk1 phosphorylates the anaphase-promoting complex-cyclosome during mitosis, which is a prerequisite for its activity but reduces the anaphase-promoting complex-cyclosome interaction with Cdc20 involving Mad2, the spindle checkpoint requires cyclin-dependent kinase activity, inhibition of Cdk overrides checkpoint-dependent arrest in eggs increasing the interaction of the anaphase-promoting complex-cyclosome with Cdc20, regulation overview
-
-
-
additional information
?
-
-
Cdks are cell cycle regulating enzymes, the spindle checkpoint requires cyclin-dependent kinase activity, regulation overview
-
-
-
additional information
?
-
-
CDKs are cell cycle-related enzymes, CDK5 activity increases 1.6fold within 5 weeks during neuronal cell differentiation induced by retinoic acid, while the activity of CDK1 and CDK2 decreases by 14.4fold, overview
-
-
-
additional information
?
-
-
constitutitve activation of CDK2-cyclin E leads to G1/S deregulation and tumor progression
-
-
-
additional information
?
-
-
cyclin-dependent kinase activity is required for apoptotic death involving the retinoblastoma protein but not inclusion formation in cortical neurons after proteasomal inhibition, Cdk2, Cdk4, and Cdk6 promote the apoptosis induced by lactacystin and other proteasome inhibitors, expression of a defective retinoblastoma protein is neuroprotective
-
-
-
additional information
?
-
-
determination of cyclin specificity of Cdk1 during cell cycle using mutant Cdk1-as1 with an enlarged ATP binding site, overview
-
-
-
additional information
?
-
-
herpes simplex virus type 1 ICP0 directs the degradation of cellular proteins associated with nuclear structures called ND10 by transactivation of promoters and gene expression involving cdks, overview, virus replication, of HSV-1, HSV-2, HMCV, and varicella-zoster virus, is inhibited by inhibition of cdks by inhibiting specific steps or activities of viral regulatory proteins, thus cdks have broad and pleiotropic effects on virus replication, overview
-
-
-
additional information
?
-
-
multisite phosphorylation and network dynamics of cyclin-dependent kinase signaling in the eukaryotic cell cycle, determination of the importance of phosphorylations of regulatory proteins in the cell cycle and biological network, CDK regulation involving positive feedback by Cdc25, Wee1, and CAK, mathematical modeling, overview
-
-
-
additional information
?
-
-
p34SEI-1 is involved in regulation of CDK4-cyclin D2 activity
-
-
-
additional information
?
-
-
plant-specific cyclin-dependent kinase CDKB1,1 and transcription factor E2Fa-DPa control the balance of mitotically dividing and endoreduplicating cells in Arabidopsis thaliana, CDKB1,1 is required to inhibit the endocycle and promote the ectopic cell divisions triggered by E2Fa-DPa, regulation model
-
-
-
additional information
?
-
-
the CDKs are involved in regulation of cell cycle and neuronal differentiation
-
-
-
additional information
?
-
-
the CDKs are involved in regulation of cell cycle and neuronal differentiation, cleavage of p35 to p25 occurs in neurons undergoing induced cell death and in brains exposed to ischaemia
-
-
-
additional information
?
-
Emericella nidulans
-
the CDKs PHOA is involved in modulation of differentiation in response to environmental conditions, including limited phosphorous, but does not play an essential role in regulation of phosphorous aquisition
-
-
-
additional information
?
-
-
the CDKs play a central role in cell cycle control, apoptosis, transcription, and neuronal functions
-
-
-
additional information
?
-
-
the enzyme interacts with kinesin-like proteins KCA1 and KCA2 and is required for their activity and protein folding, and is influenced by the phosphorylation status of KCA1 and KCA2, the interaction plays a role in the cell cycle and cell division, overview
-
-
-
additional information
?
-
-
the phosphatidylinositol-linked dopamine receptor is involved in regulation of cdk5 enzyme activity in the brain
-
-
-
additional information
?
-
-
the plant-specific kinase CDKF,1 is involved in activating phosphorylation of CDK-activating kinases in Arabidopsis
-
-
-
additional information
?
-
-
the polo-kinase 1, EC 2.7.11.21, also phosphorylated Wee1A at S53 and S123, casein kinase II, EC 2.7.11.1, also phosphorylates Wee1A at S121
-
-
-
additional information
?
-
-
there is cross-talk between the NF-kappaB/IkappaBalpha pathway and the p16/CDK4/Rb pathway in cells with IkappaBalpha being capable to substitute for the inhibitory function of p16 on CDK4, regulation
-
-
-
additional information
?
-
-
viral infection causes dysregulation of multiple human host cell cycle-regulatory proteins, cdks are involved in viral replication, overview, cdk is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production
-
-
-
additional information
?
-
-
viral K-cyclin has a much longer half-life compared to cellular cyclins because it lacks the PEST degradation sequence, the viral K-cyclin can substitute the cellular cyclins in binding to the cellular CDKs, which is important for the virus development, chimeric K-cyclin-cdks are also translocated to the nucleus, chimeric K-cyclin/cdk6 kinase is constitutively active in BC cells, chimeric K-cyclin-cyclin D2 can act as a CDK
-
-
-
additional information
?
-
P21127
CDK11p110 interacts with Hsp90, and the serine/threonine kinase CK2, the C-terminal domain of the largest subunit of RNA polymerase II is no substrate of CDK11p110, but of CK2
-
-
-
additional information
?
-
-
CDK11p58 interacts with the histone acetyltransferase HBO1 in vitro and in vivo
-
-
-
additional information
?
-
-
Cdk5 associates with amphiphysin and dynamin
-
-
-
additional information
?
-
-
CDKB ia a B1-type CDK with A-type features
-
-
-
additional information
?
-
-
determination and analysis of CDK2 consensus sequence X-S/T(P)-P-X-K/R, modeling of substrate binding, structure analysis
-
-
-
additional information
?
-
-
determination of cyclin specificity of Cdk1 with different enzyme substrates using mutant Cdk1-as1 with an enlarged ATP binding site, overview
-
-
-
additional information
?
-
-
enzyme cdk2, cdk4, and especially cdk6 interact with the KSHV viral K-cyclin, a homologue of cellular cyclin D, in BC3 cells, K-cyclin also interacts with p21Cip1 and p27Kip1 in the cells, chimeric K-cyclin/cdk6 kinase is constitutively active, chimeric K-cyclin-cyclin D2 can act as a CDK
-
-
-
additional information
?
-
-
the enzyme interacts with kinesin-like proteins KCA1 and KCA2, which possess N-terminal ATP and microtubule binding sites, as well as potential C-terminal CDK phosphorylation sites at positions 698, 849, and 853 in KCA1, and at positions 827 and 831 in KCA2, overview
-
-
-
additional information
?
-
-
autophosphorylation activity
-
-
-
additional information
?
-
-
autophosphorylation of Pfmrk, can not phosphorylate PfPK5
-
-
-
additional information
?
-
-
Cdk activity is required to fire origins of DNA replication and to prevent 'licensing' (establishing the competence) of additional origins after replication initiation
-
-
-
additional information
?
-
Q9JHU3
no detectable kinase activity towards CDKs, the Pol II carboxyl-terminal domain (CTD), histone H1 or myelin basic protein
-
-
-
additional information
?
-
-
once-per-cell-cycle replication is enforced by cyclin-Cdk-dependent phosphorylation of the prereplicative complex components Mcm2-7, Cdc6, and Orc1-6
-
-
-
additional information
?
-
-
CDK5 induces caspase-independent mitochondrial fission
-
-
-
additional information
?
-
-
Cdk1 controls timing of vacuole movement and regulates vacuole inheritance
-
-
-
additional information
?
-
-
Cdk5 is a modulator of spine morphogenesis
-
-
-
additional information
?
-
-
the CDK2-cyclin E complex is a inducer of S-phase entry and key factor for the initiation of centrosome duplication, that CDK4/6-cyclin D are the proteins that compensates for the loss of CDK2 in the initiation of centrosome duplication
-
-
-
additional information
?
-
-
phosphorylation of T161 in plant CDKA is required for activation of its associated kinase
-
-
-
additional information
?
-
-
Pho85 is a proline-directed kinase that preferentially phosphorylates the consensus sequence S/T-P-X-I/L. Cln3 contains two of these sites (Ser449 and Thr520) located precisely at the ends of the PEST region. Cln3 is an in vitro substrate of Pho85, and both proteins interact in vivo, Cln3 is a molecular target of the Pho85 kinase
-
-
-
additional information
?
-
-
identification 35 substrates from screening for cyclin B/CDK1, and investigation of the differential specificity of cyclin B/CDK1 versus cyclin A/CDK1 and cyclin A/CDK2. About half the substrates are equally well phosphorylated regardless of the cyclin or the CDK, computational analysis, overview
-
-
-
additional information
?
-
-
kinase properties of Cdk5 are similar to those of Cdk1-cyclin B. Tau and Dab1 are phosphorylated by Cdk5-p39 and Cdk5-p35 at the same sites
-
-
-
additional information
?
-
-
Pho85 is a proline-directed kinase that preferentially phosphorylates the consensus sequence S/T-P-X-I/L. Cln3 contains two of these sites (Ser449 and Thr520) located precisely at the ends of the PEST region. Cln3 is an in vitro substrate of Pho85, and both proteins interact in vivo, Cln3 is a molecular target of the Pho85 kinase
-
-
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
ATP + a protein
ADP + a phosphoprotein
show the reaction diagram
-
-
-
-
?
ATP + a protein
ADP + a phosphoprotein
show the reaction diagram
-
-
-
-
?
ATP + a protein
ADP + a phosphoprotein
show the reaction diagram
-
-
-
-
?
ATP + a protein
ADP + a phosphoprotein
show the reaction diagram
-
-
-
-
?
ATP + axonal cytoskeleton protein
ADP + phosphorylated axonal cytoskeleton protein
show the reaction diagram
-
regulated by integrin alpha1beta1
-
-
?
ATP + bloom syndrome helicase
ADP + phosphorylated bloom syndrome helicase
show the reaction diagram
-
-
-
-
?
ATP + BRCA2
ADP + phosphorylated BRCA2
show the reaction diagram
-
phosphorylates at Ser3291, phosphorylation reaches maximal levels in G2/M
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
show the reaction diagram
-
i.e. JNK3, phosphorylation inhibits JNK3 and leads to reduced phosphorylation of c-jun and to reduced apoptosis
-
-
?
ATP + Cdc20
ADP + phosphorylated Cdc20
show the reaction diagram
-
Cdk phosphorylation affects interaction of Cdc20 with Mad2 and the anaphase-promoting complex-cyclosome in HeLa cells
-
-
?
ATP + Cdc20
ADP + phosphorylated Cdc20
show the reaction diagram
-
substrate of Cdk1, rather than of Cdk2
-
-
?
ATP + Cdk1
ADP + phosphorylated Cdk2
show the reaction diagram
-
Cdk7
-
-
?
ATP + CDK1
ADP + phosphorylated CDK1
show the reaction diagram
-
CDK7 phosphorylates the activation segment or T-loop of CDK1
-
-
?
ATP + cdk2
ADP + phosphorylated cdk2
show the reaction diagram
-
CDK7 phosphorylates the activation segment or T-loop of CDK2
-
-
?
ATP + Cprk
ADP + phosphorylated Cprk
show the reaction diagram
-
i.e. Cdk5/p35-regulated kinase
-
-
?
ATP + cyclin-dependent kinase
ADP + phosphorylated cyclin-dependent kinase
show the reaction diagram
-
-
-
-
?
ATP + Dab1 protein
ADP + Dab1 phosphoprotein
show the reaction diagram
-
-
-
-
?
ATP + dephosphin
ADP + phosphorylated dephosphin
show the reaction diagram
-
Cdk5 regulates endocytosis involving dephosphin activity, overview
-
-
?
ATP + dopamine
ADP + phosphorylated dopamine
show the reaction diagram
-
phosphorylation by cdk5
-
-
?
ATP + dopamine and cAMP-regulated phosphoprotein
ADP + phosphorylated dopamine and cAMP-regulated phosphoprotein
show the reaction diagram
-
i.e. DARPP-32, phosphorylation by cdk5 at Thr75 and Thr34
-
-
?
ATP + early mitotic inhibitor 1 protein
ADP + early mitotic inhibitor 1 phosphoprotein
show the reaction diagram
-
i.e. Emi1, is phosphorylated by CDKs in mitotic but not S-phase cell extracts
-
-
?
ATP + ErbB2
ADP + phosphorylated ErbB2
show the reaction diagram
-
phosphorylation of the neuregulin receptor by Cdk5 is involved in regulation of neuregulin
-
-
?
ATP + ErbB3
ADP + phosphorylated ErbB3
show the reaction diagram
-
phosphorylation of the neuregulin receptor by Cdk5 is involved in regulation of neuregulin
-
-
?
ATP + eukaryotic elongation factor 2
ADP + phosphorylated eukaryotic elongation factor 2
show the reaction diagram
-
phosphorylation on Ser595 by Cdk2
-
-
?
ATP + Fkh2p
ADP + phosphorylated Fkh2p
show the reaction diagram
-
phosphorylation of forkhead transcription factor Fkh2p is part of regulation of cell cycle-specific gene expression, e.g. of the CLB2 cluster, Fkh2p phosphorylation by Cdc28p is regulated by complex formation with Mcm1p and Ndd1p, and phosphorylation, overview
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
show the reaction diagram
-
substrate of Cdk-A/cyclin D2
-
-
?
ATP + histone H1
ADP + phosphorylated steroid histone H1
show the reaction diagram
-
-
-
-
?
ATP + MAP1B
ADP + phosphorylated MAP1B
show the reaction diagram
-
reaction in growth cones is important for stability of microtubules
-
-
?
ATP + MEK1
ADP + phosphorylated MEk1
show the reaction diagram
-
Cdk5 regulates the ERK1/2 pathway through phosphorylation of MEK1, overview
-
-
?
ATP + MEP50 protein
ADP + MEP50 phosphoprotein
show the reaction diagram
-
a PRMT5 co-regulatory factor
-
-
?
ATP + Munc-18
ADP + phosphorylated Munc-18
show the reaction diagram
-
involved in regulation of exocytosis involving SNARE proteins, Munc-18 is required for mediating secretory responsesoverview
-
-
?
ATP + neuregulin receptor ErbB2
ADP + phosphorylated neuregulin receptor ErbB2
show the reaction diagram
-
phosphorylation at Ser1176 by Cdk5
-
-
?
ATP + neuregulin receptor ErbB3
ADP + phosphorylated neuregulin receptor ErbB3
show the reaction diagram
-
phosphorylation at Thr871 and Ser1120 by Cdk5
-
-
?
ATP + neuregulin receptor ErbB3
ADP + phosphorylated neuregulin receptor ErbB3
show the reaction diagram
-
phosphorylation at Thr871 and Ser1120 in the consensus sequence RSRSPR by Cdk5, Cdk5 associates with Erb3 in vivo
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
show the reaction diagram
-
neurofilament protein that correlates neurit outgrowth, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
show the reaction diagram
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
show the reaction diagram
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NR1 receptor
ADP + phosphorylated NR1 receptor
show the reaction diagram
-
involved in synaptic transmission, overview
-
-
?
ATP + NR2 receptor
ADP + phosphorylated NR2 receptor
show the reaction diagram
-
involved in synaptic transmission, phosphorylation of Ser1232 on the A subunit upregulates NMCAR activity, overview
-
-
?
ATP + p35 protein
ADP + p35 phosphoprotein
show the reaction diagram
-
a nuclear transcription factor, Cdk5-p25 phosphorylates p53 on Ser15, Ser33, and Ser44
-
-
?
ATP + parkin
ADP + phosphorylated parkin
show the reaction diagram
-
Ser-131 located at the linker region of parkin is the major Cdk5 phosphorylation site, phosphorylation by Cdk5 decreases the auto-ubiquitylation of parkin, parkin S131A mutant has 40% lower phosphorylation levels in vivo than wild-type parkin
-
-
?
ATP + pocket protein p107
ADP + phosphorylated pocket protein 107
show the reaction diagram
-
hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + pocket protein p130
ADP + phosphorylated pocket protein 130
show the reaction diagram
-
hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + progesterone receptor
ADP + phosphorylated progesterone receptor
show the reaction diagram
-
cyclin-dependent kinase activity is required for progesterone receptor PR function, the phosphorylation of the receptor protein has little effect, but cyclin A/Cdk2 acts as a progesterone receptor coactivator via stimulation of PR transcription, Cdk2-cyclin A is PR-dependently recruited to the PR promoter binding to cyclin A, mechanism involving SCR-1 and regulation, overview
-
-
?
ATP + progesterone receptor
ADP + phosphorylated progesterone receptor
show the reaction diagram
-
cyclin A2/Cdk2 phosphorylates progesterone receptor in vivo at Ser20 and Ser676, Ser162, Ser190 and Ser400
-
-
?
ATP + protein
ADP + phosphoprotein
show the reaction diagram
Emericella nidulans
-
NIMA is a cell cycle regulated protein kinase required, in addition to p34cdc2/cyclin B, for initiation of mitosis. NIMA accumulates when cells are arrested in G2 and is degraded as cells traverse mitosis. NIMA degradation during mitosis is required for correct mitotic progression in Aspergillus nidulans
-
-
?
ATP + Rad9 protein
ADP + Rad9 phosphoprotein
show the reaction diagram
-
a DNA damage response mediator
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
show the reaction diagram
-
i.e. Rb protein
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
show the reaction diagram
-
i.e. Rb protein
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
show the reaction diagram
-
i.e. Rb protein, hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
show the reaction diagram
-
phosphorylation by CDK4/cyclin D at one site, or by CDK2/cyclin E or A at multiple sites in the cell cycle G1 phase
-
-
?
ATP + retinoblastoma protein
ADP + retinoblastoma phosphoprotein
show the reaction diagram
-
a tumor suppressor protein
-
-
?
ATP + retinoblastoma-related protein
ADP + phosphorylated retinoblastoma-related protein
show the reaction diagram
-
i.e. RBR, substrate of Cdk-A/cyclin D2
-
-
?
ATP + RNA polymerase II
ADP + phosphorylated RNA polymerase II
show the reaction diagram
-
CDK7 and CDK8 phosphorylate the C-terminal domain of RNA Pol II
-
-
?
ATP + RNA polymerase II C-terminal domain
ADP + phosphorylated RNA polymerase II C-terminal domain
show the reaction diagram
-
phosphorylation by Cdk7 and Cdk9, phosphorylation at serine residues 2 and 5
-
-
?
ATP + RNA polymerase II C-terminal domain protein
ADP + RNA polymerase II C-terminal domain phosphoprotein
show the reaction diagram
-
-
-
-
?
ATP + SCR-1
ADP + phosphorylated SCR-1
show the reaction diagram
-
Cdk2-cyclin A, phosphorylation at Lys5 regulates SCR-1 interaction with the progesterone receptor
-
-
?
ATP + STAT3
ADP + phosphorylated STAT3
show the reaction diagram
-
specific phosphorylation at Ser727 by CDK5-p35, CDK5 is involved in regulation of the signal transducer and transcription activator STAT3 in brain and muscle
-
-
?
ATP + STAT3
ADP + phosphorylated STAT3
show the reaction diagram
-
substrate of CDK5
-
-
?
ATP + STAT3 protein
ADP + STAT3 phosphoprotein
show the reaction diagram
-
Cdk5 phosphorylates at Ser727
-
-
?
ATP + T-cell protein tyrosine phosphatase
ADP + phosphorylated T-cell protein tyrosine phosphatase
show the reaction diagram
-
phosphorylation of the two splicing varaints TC45 and TC48 at Ser304 in a cell cycle-dependent manner, optimally in mitosis, overview
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
show the reaction diagram
-
cdk5 substrate in brain, Cdk5-p25 or Cdk5-p35
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
show the reaction diagram
-
hyperactivated Cdk5-p25
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
show the reaction diagram
-
Cdk5 phosphorylates at S202, S235, and S404, phosphorylation at S235 primes it for phosphorylation of T231 by GSK3beta, phosphorylating tau protein at S404 primes tau protein for a sequential phosphorylation of S400 and S396 by GSK3beta
-
-
?
ATP + Tau protein
ADP + Tau phosphoprotein
show the reaction diagram
-
Cdk5-p25 has a stronger Tau-phosphorylating activity than Cdk5-p35 in neurons
-
-
?
ATP + Varicella-Zoster virus IE63 protein
ADP + phosphorylated Varicella-Zoster virus IE63 protein
show the reaction diagram
-
phosphorylation at Ser224 by CDK1 in vivo is required for correct localization of the virus protein, e.g. in the host cytoplasm during latency, S224A mutation leads to inhibition of phosphorylation and exclusive localization of IE63 protein in the nucleus
-
-
?
ATP + VGCC
ADP + phosphorylated NR1 receptor
show the reaction diagram
-
a voltage-dependent calcium channel, phosphorylation within the intracellular loop of the channel inhibiting interaction with SNARE proteins, SNAP-25, and synaptotagmin I required for neurotransmitter release, overview
-
-
?
ATP + Wee1A
ADP + phosphorylated Wee1A
show the reaction diagram
-
phosphorylation at S123, S53, and S121 promotes binding of Wee1A by beta-TrCP, the beta-transducin repeat-containing protein, which is the substrate recognition component of the ubiquitin ligase, leading to proteasomal degradation of Wee1A, overview
-
-
?
ATP + [elongation factor 2]
ADP + [elongation factor 2]phosphate
show the reaction diagram
-
the enzyme phosphorylates Ser595. Ser595 phosphorylation varies during the cell cycle and is required for efficient Thr56 phosphorylation (by elongation factor 2 kinase) in vivo
-
-
?
ATP + [tau protein]
ADP + [O-phospho-tau protein]
show the reaction diagram
-
substrate of CDK5 in the central nervous system, see also EC 2.7.11.26, tau hyperphosphorylation is involved in neurodegeneration and ALzheimer's disease, tau protein phosphorylation by CDK5 is involved in apoptosis in cortical cells
-
-
?
ATP + [tau-protein]
ADP + O-phospho -[tau-protein]
show the reaction diagram
-
cdk5 substrate in brain, cdk5 associated with p39, tau is a microtubule-associated and developmentally regulated protein involved in axonal development in neurons, tau phosphorylation by cyclin-dependent kinase 5/p39 during brain development reduces its affinity for microtubules, reaction of EC 2.7.11.26
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
show the reaction diagram
-
-
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
show the reaction diagram
-
activity in organisms with mutated APP and tau, not in wild-type, overview
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
show the reaction diagram
-
cdk5 associated with p25, cdk5 substrate in brain
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
show the reaction diagram
-
hyperphosphorylation of tau by CDK5 is involved in apoptosis and neurodegeneration in Alzheimer's disease, overview
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
show the reaction diagram
-
tau is microtubule-associated, phopshorylation at T231 by CDK5 causes its release into the cytoplasm
-
-
?
additional information
?
-
-, Q01917
-
-
-
-
additional information
?
-
O76039
the gene coding for the enzyme is a candidate for the following disorders: Nance-Horan syndrome, oral-facial-digital syndrome type 1, and nonsyndromic sensorineural deafness
-
-
-
additional information
?
-
-
enzyme is required for initiation of meiosis and sporulation
-
-
-
additional information
?
-
-
enzyme may play a role in the regulation of plant growth and development
-
-
-
additional information
?
-
P39951
enzyme is required for mitosis
-
-
-
additional information
?
-
-
CDK4 amplification might contribute to oncogenesis
-
-
-
additional information
?
-
-
the cdc2 protein kinase plays a role in transcriptional regulation
-
-
-
additional information
?
-
-
mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16INK4a
-
-
-
additional information
?
-
P50750
CDK9 is the catalytic subunit of a general RNA polymerase II elongation factor termed p-TEFb which is targeted by the human immunodeficiency virus Tat protein to activate elongation of the integrated proviral genome
-
-
-
additional information
?
-
-
CDK9 is the catalytic subunit of a general RNA polymerase II elongation factor termed p-TEFb which is targeted by the human immunodeficiency virus Tat protein to activate elongation of the integrated proviral genome
-
-
-
additional information
?
-
-
enzyme is required for M phase in meiotic and mitotic cell divisions, but not for S phase
-
-
-
additional information
?
-
P34117
enzyme is involved in Dictyostelium differentiation rather than growth
-
-
-
additional information
?
-
Q05006
control point in cell cycle
-
-
-
additional information
?
-
Q9W739, -
the enzyme is a component of maturation-promoting factor
-
-
-
additional information
?
-
-
proper regulation of p58 protein kinase is essential for normal cell cycle progression in these cells
-
-
-
additional information
?
-
-
PISSLRE could be involved in processes distinct from cell proliferation
-
-
-
additional information
?
-
-
negative regulatory factors of the PHO system
-
-
-
additional information
?
-
-
enzyme plays a central role in control of the mitotic cell cycle
-
-
-
additional information
?
-
P49336
human K35-cyclin C might be functionally associated with the mammalian transcription apparatus, perhaps involved in relaying growth-regulatory signals
-
-
-
additional information
?
-
-
enzyme is required both for entry into S phase and mitosis
-
-
-
additional information
?
-
-
enzyme is required for both the G1-S and G2-M transitions during mitotic growth, and also for the second meiotic nuclear division
-
-
-
additional information
?
-
Q04859
potential function in sensory cells
-
-
-
additional information
?
-
-
the enzyme is required during both G1 and G2 phases of the cell division cycle
-
-
-
additional information
?
-
P24788
enzyme may have a critical function during normal embryonic development and continues to be expressed in differentiated adult tissues
-
-
-
additional information
?
-
-
key component of the eukaryotic cell cycle, which is required for G1 to S-phase transition and for entry into mitosis
-
-
-
additional information
?
-
P30285, Q03147
enzyme is involved in signal transduction process of pattern formation in the hindbrain
-
-
-
additional information
?
-
-
Kin28 may be a cyclin dependent kinase which is required for cell proliferation
-
-
-
additional information
?
-
P32581
enzyme is required for induction of meiosis
-
-
-
additional information
?
-
P20793
enzyme plays an important role in spermatogenesis
-
-
-
additional information
?
-
P20794
enzyme plays an important role in spermatogenesis
-
-
-
additional information
?
-
-
TFIIH is a multisubunit complex, containing ATPase, helicases, and kinase subunit of TFIIH. In mitosis the CDK7 subunit of TFIIH and the largest subunit of RNAPII become hyperphosphorylated. MPF-induced phosphorylation of CDK7 results in inhibition of the TFIIH-associated kinase and transcription activities
-
-
-
additional information
?
-
P38973, P54665, P54666
enzyme may be involved in controlling aspects of the cell cycle which are linked to the differentiation of the parasite during its complex life cycle
-
-
-
additional information
?
-
-
csk1 may encode a protein kinase physically associated with mcs2 or alternatively may function as an upstream activator of the mcs2-associated kinase
-
-
-
additional information
?
-
-
enzyme is involved in negative regulation of meiotic maturation of Xenopus oocytes
-
-
-
additional information
?
-
Q63699
Cdk2 protein might be required for entry into the S phase of the cell cycle in FRTL-Tc cells
-
-
-
additional information
?
-
-
CDK4 gene is a melanoma-predisposing gene
-
-
-
additional information
?
-
P38973, P54665, P54666
enzyme is involved in controlling aspects of the cell cycle which are linked to the differentiation of the parasite during its complex life cycle
-
-
-
additional information
?
-
P50613
cdk7 is a subunit of the transcription/DNA repair factor TFIIH, cdk7 may phosphorylate the carboxy-terminal domain of RNA pol II in the absence of promoter opening
-
-
-
additional information
?
-
-
can properly regulate the cell cycle
-
-
-
additional information
?
-
-
abnormal phosphorylation of tau in dividing cells leads to its accumulation in the cytosol as microtubule-free form, Cdk5 is involved in neurodegenerative mechanisms
-
-
-
additional information
?
-
-
CDK5-dependent clustering of endoplasmic reticulum ER and mitochondria during ceramide-mediated neuronal death: neurotoxic calcium transfer from ER to mitochondria is regulated by cyclin-dependent kinase 5-dependent phosphorylation of tau, inhibition of the process leads to cell death
-
-
-
additional information
?
-
-
naturally occurring V717I mutation of the amyloid precursor protein APP in a CT100 fragment of mutants leads to augmented age-dependent tau phosphorylation, followed by increased activation status of mitogen-activated protein kinase family members, e.g. ERK1/2, p38, and c-Jun NH2-terminal kinase, compared to the wild-type organism, naturally occurring V337M mutation of tau protein of mutants leads to age-dependent memory deficits
-
-
-
additional information
?
-
-
naturally occurring V717I mutation of the amyloid precursor protein APP in a CT100 fragment of organisms with Alzheimer's disease leads to augmented age-dependent tau phosphorylation, followed by increased activation status of mitogen-activated protein kinase family members, e.g. ERK1/2, p38, and c-Jun NH2-terminal kinase, compared to the wild-type organism, naturally occurring V337M mutation of tau protein of patients suffering from Alzheimer's disease leads to age-dependent memory deficits
-
-
-
additional information
?
-
-
regulation mechanisms, overview
-
-
-
additional information
?
-
-
CDK is involved in control of cell differentiation and organogenesis
-
-
-
additional information
?
-
-
Cdk-A/cyclin D2 is involved in DNA replication progress and cell proliferation
-
-
-
additional information
?
-
-
CDK-cyclins and CDK inhibitory proteins are involved in the cell cycle regulation and of vascular cell proliferation and migration, as well as in the control of neointimal thickening, modeling, overview
-
-
-
additional information
?
-
-
Cdk1/cyclin B is induced in cells with dysregulated cell cycle, e.g. after infection with the human cytomegalovirus, regulation mechanisms, overview
-
-
-
additional information
?
-
P21127
CDK11p110 is involved in transcription and RNA processing
-
-
-
additional information
?
-
-
CDK11p58 interacts with the histone acetyltransferase HBO1 in vitro and in vivo, CDK11p58 acts as a regulator of HBO1 activity in eukaryotic transcription
-
-
-
additional information
?
-
-
CDK4 governs cell cycle progression through the G1 phase, CDK2 is involved in all cell cycle phases, overview
-
-
-
additional information
?
-
-
Cdk5 is crucial for stability of axons and growth cones in retina, overview
-
-
-
additional information
?
-
-
Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins
-
-
-
additional information
?
-
-
Cdk5 regulates Akt activation and cell survival through the neuregulin-mediated PI 3-kinase signaling pathway, null mutants show lower phosphatidylinositol 3-kinase activity, Cdk5-p35 mediates neuroprotection
-
-
-
additional information
?
-
-
Cdk5 regulation, overview, Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins, and is critical for neuronal survival, deregulation of Cdk5 occurs in neurodegeneration
-
-
-
additional information
?
-
-
Cdk5 regulation, overview, Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins, deregulation of Cdk5 occurs in neurodegeneration
-
-
-
additional information
?
-
-
Cdk5 regulation, overview, Cdk5 regulates endocytosis through association with amphiphysin and dynamin, Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins, deregulation of Cdk5 occurs in neurodegeneration
-
-
-
additional information
?
-
-
Cdk5-p35 is negatively regulated by interaction with membranes in brain and liver, mechanism
-
-
-
additional information
?
-
-
CDK6/cyclin D1 enhances the transition of cells through the G1 phase of the cell cycle, CDK6 without bound cyclin D1 associates with the androgen receptor AR and enhances, independently of its kinase activity, its transcriptional activity in presence of dihydrotestosterone in prostate cancer cells, this stimulation is highly exaggerated with AR mutant T877A found in prostate cancer, thus CDK6 is probably important for prostate cancer development, CDK6 is no essential for stimulation of AR, overview
-
-
-
additional information
?
-
-, Q8GVD7, Q8GVD8
CDKA1 is involved in cell cycle regulation and dormancy
-
-
-
additional information
?
-
-
CDKB and CDKA are regulated through phosphorylation and cyclins A and B during the cll cycle, regulation overview
-
-
-
additional information
?
-
-, Q8GVD7, Q8GVD8
CDKB1 is involved in cell cycle regulation and dormancy
-
-
-
additional information
?
-
-
Cdks are cell cycle regulating enzymes, Cdk1 phosphorylates the anaphase-promoting complex-cyclosome during mitosis, which is a prerequisite for its activity but reduces the anaphase-promoting complex-cyclosome interaction with Cdc20 involving Mad2, the spindle checkpoint requires cyclin-dependent kinase activity, inhibition of Cdk overrides checkpoint-dependent arrest in eggs increasing the interaction of the anaphase-promoting complex-cyclosome with Cdc20, regulation overview
-
-
-
additional information
?
-
-
Cdks are cell cycle regulating enzymes, the spindle checkpoint requires cyclin-dependent kinase activity, regulation overview
-
-
-
additional information
?
-
-
CDKs are cell cycle-related enzymes, CDK5 activity increases 1.6fold within 5 weeks during neuronal cell differentiation induced by retinoic acid, while the activity of CDK1 and CDK2 decreases by 14.4fold, overview
-
-
-
additional information
?
-
-
constitutitve activation of CDK2-cyclin E leads to G1/S deregulation and tumor progression
-
-
-
additional information
?
-
-
cyclin-dependent kinase activity is required for apoptotic death involving the retinoblastoma protein but not inclusion formation in cortical neurons after proteasomal inhibition, Cdk2, Cdk4, and Cdk6 promote the apoptosis induced by lactacystin and other proteasome inhibitors, expression of a defective retinoblastoma protein is neuroprotective
-
-
-
additional information
?
-
-
determination of cyclin specificity of Cdk1 during cell cycle using mutant Cdk1-as1 with an enlarged ATP binding site, overview
-
-
-
additional information
?
-
-
herpes simplex virus type 1 ICP0 directs the degradation of cellular proteins associated with nuclear structures called ND10 by transactivation of promoters and gene expression involving cdks, overview, virus replication, of HSV-1, HSV-2, HMCV, and varicella-zoster virus, is inhibited by inhibition of cdks by inhibiting specific steps or activities of viral regulatory proteins, thus cdks have broad and pleiotropic effects on virus replication, overview
-
-
-
additional information
?
-
-
multisite phosphorylation and network dynamics of cyclin-dependent kinase signaling in the eukaryotic cell cycle, determination of the importance of phosphorylations of regulatory proteins in the cell cycle and biological network, CDK regulation involving positive feedback by Cdc25, Wee1, and CAK, mathematical modeling, overview
-
-
-
additional information
?
-
-
p34SEI-1 is involved in regulation of CDK4-cyclin D2 activity
-
-
-
additional information
?
-
-
plant-specific cyclin-dependent kinase CDKB1,1 and transcription factor E2Fa-DPa control the balance of mitotically dividing and endoreduplicating cells in Arabidopsis thaliana, CDKB1,1 is required to inhibit the endocycle and promote the ectopic cell divisions triggered by E2Fa-DPa, regulation model
-
-
-
additional information
?
-
-
the CDKs are involved in regulation of cell cycle and neuronal differentiation
-
-
-
additional information
?
-
-
the CDKs are involved in regulation of cell cycle and neuronal differentiation, cleavage of p35 to p25 occurs in neurons undergoing induced cell death and in brains exposed to ischaemia
-
-
-
additional information
?
-
Emericella nidulans
-
the CDKs PHOA is involved in modulation of differentiation in response to environmental conditions, including limited phosphorous, but does not play an essential role in regulation of phosphorous aquisition
-
-
-
additional information
?
-
-
the CDKs play a central role in cell cycle control, apoptosis, transcription, and neuronal functions
-
-
-
additional information
?
-
-
the enzyme interacts with kinesin-like proteins KCA1 and KCA2 and is required for their activity and protein folding, and is influenced by the phosphorylation status of KCA1 and KCA2, the interaction plays a role in the cell cycle and cell division, overview
-
-
-
additional information
?
-
-
the phosphatidylinositol-linked dopamine receptor is involved in regulation of cdk5 enzyme activity in the brain
-
-
-
additional information
?
-
-
the plant-specific kinase CDKF,1 is involved in activating phosphorylation of CDK-activating kinases in Arabidopsis
-
-
-
additional information
?
-
-
the polo-kinase 1, EC 2.7.11.21, also phosphorylated Wee1A at S53 and S123, casein kinase II, EC 2.7.11.1, also phosphorylates Wee1A at S121
-
-
-
additional information
?
-
-
there is cross-talk between the NF-kappaB/IkappaBalpha pathway and the p16/CDK4/Rb pathway in cells with IkappaBalpha being capable to substitute for the inhibitory function of p16 on CDK4, regulation
-
-
-
additional information
?
-
-
viral infection causes dysregulation of multiple human host cell cycle-regulatory proteins, cdks are involved in viral replication, overview, cdk is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production
-
-
-
additional information
?
-
-
viral K-cyclin has a much longer half-life compared to cellular cyclins because it lacks the PEST degradation sequence, the viral K-cyclin can substitute the cellular cyclins in binding to the cellular CDKs, which is important for the virus development, chimeric K-cyclin-cdks are also translocated to the nucleus, chimeric K-cyclin/cdk6 kinase is constitutively active in BC cells, chimeric K-cyclin-cyclin D2 can act as a CDK
-
-
-
additional information
?
-
-
CDK5 induces caspase-independent mitochondrial fission
-
-
-
additional information
?
-
-
Cdk1 controls timing of vacuole movement and regulates vacuole inheritance
-
-
-
additional information
?
-
-
Cdk5 is a modulator of spine morphogenesis
-
-
-
additional information
?
-
-
the CDK2-cyclin E complex is a inducer of S-phase entry and key factor for the initiation of centrosome duplication, that CDK4/6-cyclin D are the proteins that compensates for the loss of CDK2 in the initiation of centrosome duplication
-
-
-
additional information
?
-
-
Pho85 is a proline-directed kinase that preferentially phosphorylates the consensus sequence S/T-P-X-I/L. Cln3 contains two of these sites (Ser449 and Thr520) located precisely at the ends of the PEST region. Cln3 is an in vitro substrate of Pho85, and both proteins interact in vivo, Cln3 is a molecular target of the Pho85 kinase
-
-
-
COFACTOR
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
ATP
-
the binding site is a deep pocket lined by hydrophobic residues, enzyme affinity of cdk2 for ATP is not influenced by phosphorylation of the activation loop
ATP
-
dependent on
ATP
-
ATP binding pocket structure, the pocket is a cleft located at the interface between two domains, involvd residues, overview
ATP
Emericella nidulans
-
-
ATP
-, Q8GVD7, Q8GVD8
;
ATP
-
mutant Cdk1-as1 has an enlarged ATP binding site
ATP
-
binding at the active site between the C- and N-terminal enzyme domains
cyclin
-
dependent on as regulatory subunit
-
cyclin
-
active CDK-cyclin oscillates during the cell cycle
-
cyclin
-
regulatory subunit of CDK
-
cyclin
-
regulatory subunit of the CDK
-
cyclin
-
dependent on
-
cyclin
-
;
-
cyclin
-
-
-
cyclin A
-
competes with cyclin E isoforms
-
cyclin A
-
is required as regulatory subunit of CDK2 in cell cycle S, M, and G1 phases
-
cyclin A
-
required regulatory subunit of CDKs
-
cyclin A
-
regulatory subunit of Cdk2
-
cyclin A
-
complexes with CDKA
-
cyclin A
-
in complex with CDK2
-
cyclin A
-
-
-
cyclin A
-
full activation of CDK2 requires both binding of cyclin A or cyclin E and phosphorylation of residue T160 in the activation segment (also known as the T-loop) by the CDK-activating kinase
-
cyclin A
-
cofactor of CDK2
-
cyclin A
-
cyclin Acyclin-dependent enzyme. Phosphorylation of elongation factor 2 on Ser595 by the cyclin A-dependent enzyme directly stimulates phosphorylation of elongation factor 2 by elongation factor 2 kinase on Thr56
-
cyclin B
-
stabilizing regulatory subunit of Cdk1
-
cyclin B
-
is required as regulatory subunit of CDK2 in cell cycle G2 and M phases
-
cyclin B
-
regulatory subunit of CDK1
-
cyclin B
-
regulatory subunit cyclin B and catalytic subunit Cdk1, HCMV-infection leads to accumulation of active cyclin B in cells due to increased synthesis and reduced degradation
-
cyclin B
-
interacts with and activates Cdc2/Cdk1
-
cyclin B
-
regulatory subunit of CDK1
-
cyclin B
-
regulatory subunit of CDKA,1
-
cyclin B
-
complexes with CDKA and CDKB
-
cyclin B
-
-
-
cyclin B
-
cofactor of CDK1
-
cyclin B1
-
required regulatory subunit of CDKs
-
cyclin B2
-
i.e. Clb2
-
cyclin B5
-
i.e. Clb5, specificity mechanism, overview
-
cyclin C
-
cofactor of CDK3
-
cyclin Clb5
-
-
-
cyclin Clb6
-
-
-
cyclin D
-
is required as regulatory subunit of CDK4
-
cyclin D
-
required regulatory subunit of CDKs
-
cyclin D
-
-
-
cyclin D
-
in complex with CDK4
-
cyclin D
-
cofactor of CDK4 and CDK6
-
cyclin D1
-, Q8GVD7, Q8GVD8
regulatory subunit of CDKs, SwissProt-ID Q8GVE0; regulatory subunit of CDKs, SwissProt-ID Q8GVE0
-
cyclin D1
-
regulatory subunit of Cdk2
-
cyclin D1
-
regulatory subunit of CDK6, activates
-
cyclin D1
-
cofactor of CDK4
-
cyclin D2
-
regulatory subunit of the holoenzyme formed with CDK4
-
cyclin D2
-
regulatory subunit, dependent on
-
cyclin D2
-
required regulatory subunit of cdk6
-
cyclin D2
-
expression analysis in response to Cdk-Activity and phytohormone levels, e.g. of cytokinin and abscisic acid, cytokinin stimulates sucrose-dependently the expression of cyclin D2 at the late germination state of the embryo
-
cyclin D3
-, Q8GVD7, Q8GVD8
regulatory subunit of CDKs, SwissProt-ID Q8GVD9; regulatory subunit of CDKs, SwissProt-ID Q8GVD9
-
cyclin D3
-
PFTK1 specifically interacted with cyclin D3
-
cyclin D3
-
cofactor of CDK11
-
cyclin E
-
stabilizing regulatory subunit of Cdk2
-
cyclin E
-
dependent on, high expression level in breast cancer cells, activating low molecular weight forms L, T1, and T2 of the cyclin E are expressed in breast cancer, modeling of CDK2 activation by cyclin E, overview
-
cyclin E
-
is required as regulatory subunit of CDK2 in cell cycle G1 phase
-
cyclin E
-
regulatory subunit of Cdk2
-
cyclin E
-
required regulatory subunit of CDKs
-
cyclin E
-
interacts with and activates Cdk2
-
cyclin E
-
in complex with CDK2
-
cyclin E
-
full activation of CDK2 requires both binding of cyclin A or cyclin E and phosphorylation of residue T160 in the activation segment (also known as the T-loop) by the CDK-activating kinase
-
cyclin E
-
-
-
cyclin E
-
cofactor of CDK2
-
cyclin E
-
cofactor of CDK2
-
cyclin E2
-
cofactor of CDK3
-
cyclin H
-
interacts with CDKF,1, dependent on, CDK activity requires specific cyclin partners
-
cyclin H
-
dependent on, regulatory subunit
-
cyclin H
-
cofactor of CDK7
-
cyclin K
-
-
-
cyclin L
-
cofactor of CDK11
-
cyclin Pcl1
-
-
-
cyclin Pcl10
-
-
-
cyclin Pcl2
-
-
-
cyclin Pcl3
-
-
-
cyclin Pcl4
-
-
-
cyclin Pcl5
-
-
-
cyclin Pcl6
-
-
-
cyclin Pcl7
-
-
-
cyclin Pcl8
-
-
-
cyclin Pcl9
-
-
-
cyclin Pho80
-
-
-
cyclin T
Q5JK68, Q6I5Y0
CDKC1 and CDKC2 form P-TEFb-like complexes with cyclin T14 and cyclin T15; CDKC1 and CDKC2 form P-TEFb-like complexes with cyclin T14 and cyclin T15
-
cyclin T
Q8W4P1
-
-
cyclin T
-
-
-
cyclin T
-
cofactor of CDK9
-
cyclin V
-
regulatory subunit of CDK6
-
cyclin-1
-
regulatory subunit
-
additional information
-
viral K-cyclin has a much longer half-life compared to cellular cyclins because it lacks the PEST degradation sequence, the viral K-cyclin can substitute the cellular cyclins in binding to the cellular CDKs, which is important for the virus development
-
additional information
-
determination of cyclin specificity of Cdk1 during cell cycle and with different enzyme substrates, overview
-
additional information
-
Pho85 associates with 10 Pho85 cyclins
-
METALS and IONS
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
Ca2+
-
stimulates Cdk5, Ca2+/calmodulin induce the phosphorylation of p35 by Cdk5 after stimulation of the Ca2+-permeable cation channels NMDA receptor and kainate receptor, leading to cleavage of p35 to p25
Ca2+
-
induces cleavage of p35 to p25 by calpains, which changes the localization of Cdk5 from the particluate to the soluble fraction
Ca2+
-
induces cleavage of p35 to p25 by calpains, which changes the localization of Cdk5 from the particulate to the soluble fraction
Cd2+
-
can partially substitue Mg2+
Co2+
-
can partially substitue Mg2+
Mg2+
-
-
Mg2+
-
dependent on, Mg2+ is the physiologic metal ion, other divalent cations are able to support nucleotide binding, but only Mn2+, Co2+, and Cd2+ can substitute Mg2+ in supporting the catalytic activity
Mg2+
-
-
Mg2+
-
coordinated by D145
Mn2+
-
can partially substitue Mg2+
Mn2+
-
required
INHIBITORS
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
(-)-cis-5,7-dihydroxyphenyl-8-[4-(3-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-one hydrochloride hemihydrate
-
-
-
(1S,2R,3R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2yl]amino]cyclohexane-1,2-diol
-
-
-
(2R)-2-hydroxy-3-[[9-(propan-2-yl)-6-[[4-(pyridin-2-yl)benzyl]amino]-9H-purin-2-yl]amino]propyl L-valinate
-
-
(2R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]propane-1,2-diol
-
-
-
(2S)-4-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]butane-1,2-diol
-
-
-
(3-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]phenyl)acetonitrile
-
-
(3-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]phenyl)methanol
-
-
(3-[[4-amino-6-(cyclohexylmethoxy)pyrimidin-2-yl]amino]phenyl)acetonitrile
-
41% inhibition at 0.01 mM
(3R,5S)-5-(hydroxymethyl)-1-[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]- purin-2-yl]pyrrolidin-3-ol
-
-
-
(3R,5S)-5-(hydroxymethyl)-1-[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]-purin-2-yl]pyrrolidin-3-ol
-
-
-
(3Z)-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
-
IC50 for CDK1 is above 0.016 mM
(3Z)-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
-
IC50 for mrk is 0.0040 mM, and for PK5 0.15 mM, only weak inhibition of parasite strains D6 and W2 growth
(3Z)-3-[2-(4-bromophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
IC50 for CDK1 is 0.012 mM
(3Z)-3-[2-(4-bromophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
IC50 for mrk is 0.0035 mM, and for PK5 0.13 mM, only weak inhibition of parasite strains D6 and W2 growth
(3Z)-5-bromo-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
-
IC50 for CDK1 is 0.030 mM
(3Z)-5-bromo-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
-
IC50 for mrk is 0.0031 mM, and for PK5 0.12 mM, only weak inhibition of parasite strains D6 and W2 growth
(3Z)-5-bromo-3-[2-(4-fluorophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
IC50 for CDK1 is 0.029 mM
(3Z)-5-bromo-3-[2-(4-fluorophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
IC50 for mrk is 0.0014 mM, and for PK5 0.19 mM, only weak inhibition of parasite strains D6 and W2 growth
(3Z)-5-bromo-3-[2-(4-methylphenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
IC50 for CDK1 is 0.029 mM
(3Z)-5-bromo-3-[2-(4-methylphenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
IC50 for mrk is 0.0029 mM, and for PK5 0.12 mM, only weak inhibition of parasite strains D6 and W2 growth
(4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-3-yl)hydrazine trihydrochloride
-
-
(4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]phenyl)acetonitrile
-
-
(4-[[4-amino-6-(cyclohexylmethoxy)pyrimidin-2-yl]amino]phenyl)acetonitrile
-
-
(5Z)-2-(benzylamino)-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-(butylamino)-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-(cyclopropylamino)-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-(methoxyamino)-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-(methylamino)-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-(phenylamino)-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[(2,6-dichlorobenzyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[(2-bromobenzyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[(2-chlorobenzyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[(2-methoxybenzyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[(2-phenylethyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[(2-pyridin-2-ylethyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[(3-hydroxy-2-phenylpropyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[(3-phenylpropyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[(pyridin-2-ylmethyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[methyl(thiophen-2-ylmethyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[[(1R)-1-benzyl-2-hydroxyethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[[(1R)-2-hydroxy-1-phenylethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[[(1R)-2-methoxy-1-phenylethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[[(1R,2S)-2-phenylcyclopropyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[[(1S)-1-benzyl-2-hydroxyethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[[(1S)-2-hydroxy-1-phenylethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[[2-(2-chlorophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[[2-(2-ethoxyphenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[[2-(2-fluorophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[[2-(2-methoxyphenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[[2-(3-chlorophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[[2-(3-fluorophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[[2-(4-bromophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[[2-(4-chlorophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[[2-(4-fluorophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-2-[[2-(4-methoxyphenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-5-(quinolin-6-ylmethylidene)-2-(thiophen-2-ylmethyl)-1,3-thiazol-4(5H)-one
-
-
(5Z)-5-(quinolin-6-ylmethylidene)-2-[(2-thiophen-2-ylethyl)amino]-1,3-thiazol-4(5H)-one
-
-
(5Z)-5-(quinolin-6-ylmethylidene)-2-[(thiophen-2-ylmethyl)amino]-1,3-thiazol-4(5H)-one
-
-
(R)-roscovitine
-
specific inhibitor of CDK1, 2, 5, and 7
(R)-roscovitine
-
a membrane permeable cyclin-dependent kinase inhibitor
(R)-roscovitine
-
-
1,2-di(2-pyridyl)-1H-pyrazolo[3,4-c]pyridazine
-
-
1,2-dimethyl-1H-pyrazolo[3,4-c]pyridazine
-
-
1,25-dihydroxyvitamin D3
-
inhibition of CDK2 activity by 1,25-dihydroxyvitamin D3 is associated with decreased T160 phosphorylation, a residue whose phosphorylation in the nucleus is essential for CDK2 activity. 1,25-dihydroxyvitamin D3 increases the stability of the cyclin-dependent kinase inhibitor p27KIP1. Ectopic expression of cyclin E is sufficient to overcome 1,25-dihydroxyvitamin D3-mediated cytoplasmic mislocalization of CDK2 and all antiproliferative effects of 1,25-dihydroxyvitamin D3, yet endogenous levels of cyclin E or binding to CDK2 are not affected by 1,25-dihydroxyvitamin D3. Targeting CDK2 to the nucleus of 1,25-dihydroxyvitamin D3-sensitive cancer cells blocked G1 accumulation and growth inhibition by 1,25-dihydroxyvitamin D3
-
1-(1-acetylpiperidin-4-yl)-8-(cyclopentylamino)-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-(4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-3-yl)-3-ethylurea
-
-
1-(4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-3-yl)-3-phenylurea
-
-
1-(5-cyclobutyl-thiazol-2-yl)-3-isoquinolin-5-yl-urea
-
competitive inhibitor
1-acetyl-3-amino-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazine
-
-
1-amino-3H-dibenzo[f,h]pyrazolo[3,4-c]cinnoline
-
-
1-benzyl-8-(cyclopentylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]-quinazoline-3-carboxamide
-
-
1-methyl-8-([1-[(4-methylpiperazin-1-yl)carbonyl]piperidin-4-yl]amino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[(1-methylpiperidin-4-yl)amino]-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[(pyridin-2-ylmethyl)amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[(pyridin-3-ylmethyl)amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[(pyridin-4-ylmethyl)amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[[1-(methylsulfonyl)piperidin-4-yl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[[1-(phenylcarbonyl)piperidin-4-yl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[[1-(phenylsulfonyl)piperidin-4-yl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[[2-(morpholin-4-yl)ethyl]amino]-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[[2-(piperidin-1-yl)ethyl]amino]-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[[3-(4-methylpiperazin-1-yl)benzyl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[[4-(4-methylpiperazin-1-yl)benzyl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[[4-(methylsulfonyl)benzyl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-NMPP1
-
inhibits Cdk7, selective inhibition of Cdk7 in G1 prevents activation but not formation of Cdk2/cyclin complexes and delays S phase. Inhibiting Cdk7 in G2 blocks entry to mitosis and disrupts Cdk1/cyclin B complex assembly
1-[4-[(5-fluoro-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-yl)amino]phenyl]-N,N-dimethyl-L-prolinamide
-
-
2,5-hexanedione
-
activities of CDK5 in cerebral cortex of 200 or 400 mg/kg 2,5-hexanedione-treated rats are significantly decreased in both the cytosolic and membrane fractions, CDK5 activities are significantly decreased in the cytosolic fraction of spinal cord cord in 200 and 400 mg/kg 2,5-hexanedione-treated rats
2-(2-chlorophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
-
-
2-(3-bromophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
-
-
2-(3-chloro-4-piperazin-1-yl-phenylamino)-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
2-(3-chlorophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
-
-
2-(4-aminophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
-
-
2-(4-bromophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
-
-
2-(4-chlorophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
-
-
2-biphenyl-4-yl-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
-
-
2-[(3,4-dimethoxyphenyl)amino]-8-ethylpyrido[2,3-d]pyrimidin-7(8H)-one
-
-
2-[(3-amino-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-1-yl)methoxy]ethanol
-
-
2-[(4-[4-[(5-fluoro-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-yl)amino]phenyl]piperazin-1-yl)sulfonyl]-2-oxoethanol
-
-
2-[(4-[4-[(6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-yl)amino]phenyl]piperazin-1-yl)sulfonyl]-1-(methylsulfanyl)-2-oxoethanol
-
-
2-[(4-[4-[(6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-yl)amino]phenyl]piperazin-1-yl)sulfonyl]-2-oxoethanol
-
-
2-[2-(3-amino-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-1-yl)ethoxy]ethanol
-
-
2-[4-(4-acetyl-piperazin-1-yl)-phenylamino]-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
2-[4-(diethylamino)phenyl]-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
-
-
2-[4-(dimethylamino)phenyl]-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
-
-
3-acetamide-1-acetyl-4,5-diphenyl-1H-pyrazolo[3,4-c]-pyridazine
-
-
3-acetamide-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazine
-
-
3-amino-1-benzyl-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazine
-
-
3-amino-4,5-bis(p-aminophenyl)-1H-pyrazolo[3,4-c]-pyridazine
-
-
3-amino-4,5-bis(p-methoxyphenyl)-1H-pyrazolo[3,4-c]-pyridazine
-
-
3-amino-4,5-bis(p-nitrophenyl)-1H-pyrazolo[3,4-c]pyridazine
-
-
3-amino-4,5-bis(p-tert-butylphenyl)-1H-pyrazolo[3,4-c]-pyridazine
-
-
3-amino-4,5-bis(p-trifluoromethylphenyl)-1H-pyrazolo-[3,4-c]pyridazine
-
-
3-amino-4,5-di(2-furyl)-1H-pyrazolo[3,4-c]pyridazine
-
-
3-amino-4-phenyl-1H-pyrazolo[3,4-c]pyridazine
-
-
3-amino-5-(2-furyl)-1H-pyrazolo[3,4-c]pyridazine
-
-
3-amino-5-methyl-4-phenyl-1H-pyrazolo[3,4-c]pyridazine
-
-
3-amino-5-phenyl-1H-pyrazolo[3,4-c]pyridazine
-
-
3-[[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene]-5-(1,3-oxazol-5-yl)-1,3-dihydro-2H-indol-2-one
-
-
3-[[4-([[amino(imino)methyl]amino]sulfonyl)anilino]methylene]-2-oxo-2,3-dihydro-1H-indole
-
-
4-(1,3-benzothiazol-2-yl)-N-(1,3-thiazol-2-yl)thiophene-2-sulfonamide
-
-
4-(1,3-benzothiazol-2-yl)-N-(2-fluoroethyl)thiophene-2-sulfonamide
-
poor inhibition of cdk5/p25
4-(1,3-benzothiazol-2-yl)-N-(4,5-dimethyl-1,3-thiazol-2-yl)thiophene-2-sulfonamide
-
-
4-(1,3-benzothiazol-2-yl)-N-(4-methylpyridin-2-yl)thiophene-2-sulfonamide
-
-
4-(1,3-benzothiazol-2-yl)-N-(5-hydroxypyridin-2-yl)thiophene-2-sulfonamide
-
-
4-(1,3-benzothiazol-2-yl)-N-(pyridin-2-ylmethyl)thiophene-2-sulfonamide
-
-
4-(1,3-benzothiazol-2-yl)-N-hydroxythiophene-2-sulfonamide
-
-
4-(1,3-benzothiazol-2-yl)-N-[5-(morpholin-4-yl)pyridin-2-yl]thiophene-2-sulfonamide
-
-
4-(1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
-
binds to Ile10 and Asp86 in the active site of cdk2
4-(1,4-dioxo-1,4-dihydro-naphthalen-2-ylamino)-N-(2-hydroxy-ethyl)-benzenesulfonamide
-
-
4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-N-[4-(methylsulfonyl)phenyl]pyrimidin-2-amine
-
;
4-(6-acetyl-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
-
poor inhibition of cdk2/cyclin E
4-(6-amino-4-cyclohexylmethoxy-5-nitrosopyrimidin-2-ylamino)-benzenesulfonamide
-
-
4-(6-amino-4-cyclohexylmethoxy-5-nitrosopyrimidin-2-ylamino)-N-(2,3-dihydroxypropyl)-benzenesulfonamide
-
-
4-(6-amino-4-cyclohexylmethoxy-5-nitrosopyrimidin-2-ylamino)-N-(2-hydroxyethyl)benzenesulfonamide
-
-
4-(6-chloro-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
-
-
4-(6-fluoro-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
-
-
4-(6-methyl-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
-
-
4-(6-nitro-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
-
-
4-chloro-N-(cis-3-[4-[(naphthalen-1-ylacetyl)amino]-1H-imidazol-1-yl]cyclobutyl)benzamide
-
-
4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]-N-(2-methoxyethyl)benzenesulfonamide
-
;
4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]benzenesulfonamide
-
;
4-[(4-imidazo[1,2-b]pyridazin-3-ylpyrimidin-2-yl)amino]-N-methylbenzenesulfonamide
-
;
4-[2-(5-bromo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)hydrazino]benzenesulfonamide
-
-
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-(4-[[3-(1,3-oxazetidin-3-yl)propyl]sulfonyl]phenyl)pyrimidin-2-amine
-
;
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]pyrimidin-2-amine
-
;
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(propylsulfonyl)phenyl]pyrimidin-2-amine
-
;
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-[(tetrahydrofuran-2-ylmethyl)sulfonyl]phenyl]pyrimidin-2-amine
-
;
4-[4-(8-cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido-[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperazine-1-carbaldehyde
-
-
4-[4-(8-cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido-[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester
-
-
4-[4-(8-cyclopentyl-7-oxo-5-trifluoromethyl-7,8-dihydropyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester
-
-
4-[7-(4-chloro-3-fluorophenyl)-1,3-benzothiazol-2-yl]thiophene-2-sulfonamide
-
-
4-[7-(4-fluorophenyl)-1,3-benzothiazol-2-yl]thiophene-2-sulfonamide
-
poor inhibition of cdk2/cyclin E
4-[[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino]-N-(1,3-thiazol-2-yl)benzenesulfonamide
-
-
4-[[(7-oxo-6,7-dihydro-8H-[1,3]thiazolo[5,4-e]indol-8-ylidene)methyl]amino]-N-(2-pyridinyl)benzenesulfonamide
-
-
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)-N-methylbenzenesulfonamide
-
;
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
-
;
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-methylbenzenesulfonamide
-
;
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-[3-(1-methylethoxy)propyl]benzenesulfonamide
-
;
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide
-
;
4-[[4-(1-cyclopentyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
-
;
4-[[4-(1-cyclopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
-
;
4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
-
;
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]-N,N-diethylbenzamide
-
-
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]-N,N-diethylbenzenesulfonamide
-
-
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]-N,N-dimethylbenzamide
-
-
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]-N-(2-hydroxypropyl)benzenesulfonamide
-
-
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]-N-(tetrahydrofuran-2-ylmethyl)benzenesulfonamide
-
-
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]-N-1,3-thiazol-2-ylbenzenesulfonamide
-
-
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]phenol
-
-
4-[[4-amino-6-(cyclohexylmethoxy)pyrimidin-2-yl]amino]-N,N-diethylbenzamide
-
29% inhibition at 0.001 mM
4-[[4-amino-6-(cyclohexylmethoxy)pyrimidin-2-yl]amino]-N,N-diethylbenzenesulfonamide
-
33% inhibition at 0.01 mM
4-[[4-amino-6-(cyclohexylmethoxy)pyrimidin-2-yl]amino]-N,N-dimethylbenzamide
-
49% inhibition at 0.1 mM
4-[[4-amino-6-(cyclohexylmethoxy)pyrimidin-2-yl]amino]benzamide
-
-
5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole
-
cdk9 inhibitor
5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole
-
specific CDK7 and 9 inhibition drives resolution of neutrophil-dominant inflammation
5-fluoro-6,8-dimethyl-N-(4-morpholin-4-ylphenyl)-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-amine
-
-
6,7-dimethoxy-N-(3hydroxyphenyl)quinazolin-4-amine
-
-
6,8-dimethyl-N-(4-morpholin-4-ylphenyl)-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-amine
-
-
6,8-dimethyl-N-[4-[4-(methylsulfonyl)piperazin-1-yl]phenyl]-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-amine
-
-
6-(cyclohexylmethoxy)-N2-(3-methoxyphenyl)-5-nitrosopyrimidine-2,4-diamine
-
-
6-(cyclohexylmethoxy)-N2-(4-methoxyphenyl)-5-nitrosopyrimidine-2,4-diamine
-
-
6-(cyclohexylmethoxy)-N2-[3-(methylsulfanyl)phenyl]-5-nitrosopyrimidine-2,4-diamine
-
-
6-(cyclohexylmethoxy)-N2-[3-(methylsulfanyl)phenyl]pyrimidine-2,4-diamine
-
-
6-(cyclohexylmethoxy)-N2-[4-(methylsulfanyl)phenyl]-5-nitrosopyrimidine-2,4-diamine
-
-
6-acetyl-8-cyclopentyl-5-methyl-2-(4-piperazin-1-ylphenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
6-bromo-8-cyclopentyl-5-methyl-2-(4-piperazin-1-ylphenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
6-chloro-8-cyclopentyl-5-methyl-2-(4-piperazin-1-ylphenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
6-dimethylamino purine
-
potent inhibitor of CDK1/cyclin B
8-(1-ethyl-propyl)-5-methyl-2-(4-piperazin-1-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-(benzylamino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclohexylamino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]-quinazoline-3-carboxamide
-
-
8-(cyclohexylamino)-N-1-dimethyl-4,5-dihydro-1H-pyrazolo-[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-1-(2-hydroxyethyl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-1-(4-methoxyphenyl)-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-1-(4-sulfamoylphenyl)-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-1-(pyridin-2-yl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-1-phenyl-4,5-dihydro-1H-pyrazolo[4,3-h]-quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-N-1-dimethyl-4,5-dihydro-1H-pyrazolo-[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-N-hydroxy-N,1-dimethyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
-
8-(cyclopentylamino)-N-methyl-1-(1-methylpiperidin-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-N-[1-(dimethylamino)propan-2-yl]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-N-[2-(dimethylamino)ethyl]-N-1-dimethyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-amino-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-cyclopentyl-2-(4-morpholin-4-yl-phenylamino)-8Hpyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-2-(4-piperazin-1-yl-phenylamino)-5-trifluoromethyl-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-2-(4-piperazin-1-yl-phenylamino)-8Hpyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-2-(4-piperidin-1-yl-phenylamino)-8Hpyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-2-(4-[1,4]diazepan-1-yl-phenylamino)-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-2-[4-(3,3-dimethyl-piperazin-1-yl)-phenylamino]-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-2-[4-(3,5-dimethyl-piperazin-1-yl)-phenylamino]-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-2-[4-(3-hydroxy-pyrrolidin-1-yl)-phenylamino]-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-2-{4-[4-(3-hydroxy-propyl)-piperidin-1-yl]-phenylamino}-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-5,6-dimethyl-2-(4-piperazin-1-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-5-ethyl-2-(4-piperazin-1-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-5-methyl-2-(4-morpholin-4-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-5-methyl-2-(4-piperazin-1-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-5-methyl-2-(4-piperidin-1-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-5-methyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-5-methyl-7-oxo-2-(4-piperazin-1-yl-phenylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid
-
-
8-cyclopentyl-5-methyl-7-oxo-2-(4-piperazin-1-yl-phenylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester
-
-
8-cyclopentyl-5-methyl-7-oxo-2-(4-piperazin-1-yl-phenylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid methyl ester
-
-
8-cyclopentyl-6-ethyl-5-methyl-2-(4-piperazin-1-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-6-fluoro-5-methyl-2-(4-piperazin-1-ylphenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-6-iodo-5-methyl-2-(4-piperazin-1-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-ethyl-2-[4-(4-methylpiperazin-1-yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-isopropyl-5-methyl-2-(4-piperazin-1-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-[(1-acetylpiperidin-4-yl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-[(1-acetylpiperidin-4-yl)amino]-N,1-dimethyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-[(1-acetylpiperidin-4-yl)amino]-N,1-dimethyl-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-[(1-ethylpiperidin-4-yl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-[(2-hydroxyethyl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo-[4,3-h]quinazoline-3-carboxamide
-
-
8-[(3-methoxybenzyl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-[(4-bromobenzyl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo-[4,3-h]quinazoline-3-carboxamide
-
-
8-[(4-methoxybenzyl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-[[4-(acetylamino)benzyl]amino]-1-methyl-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
actinomycin D
-
is less effective than 1-NMPP1 at inhibiting Cdk2 T loop phosphorylation
aloisine-A
-
-
alsterpaullone
-
95% inhibition of CDK2 at 0.01 mM
alsterpaullone
-
-
aminopurvalanol
-
-
AMP
-
competitive inhibitor
anilinopyrimidine 32
-
-
apigenin
-
a flavonoid inhibitor of CDK6, CDK5, and CDK1
arylazopyrazole 31b
-
-
BMS-387032
-
-
-
BS-181
-
only inhibits CDK2 at concentrations lower than 1 mM, with CDK2 being inhibited 35fold less potently than CDK7
Butyrolactone
-
0.01 mM
butyrolactone-1
-
-
CDK inhibitory proteins
-
members of the family of CDK inhibitory proteins, e.g. INK4 proteins, overview, CKIs may play a role as regulators in neointimal hyperplasia
-
CDK1 inhibitor III
-
i.e. ethyl(6-hydroxy-4-phenylbenzo[4,5]furo[2,3-b])pyridine-3-carboxylate, inhibition of IE63 protein phosphorylation at Ser224 leads to exclusive localization of IE63 protein in the host nucleus
Cdk2 inhibitor II
-
-
Cdk2DN
-
inhibition of Cdk2, induces phosphorylation of ataxia-telangiectasia mutated substrates
-
Cdk4/'6 Inhibitor IV
-
-
chrysin
-
a flavonoid inhibitor of CDK6, CDK5, and CDK1
CIP (154-279)
-
-
-
Cks1
-
Cks 1 protein inactivates Cdk2, activation of Chk1 leads to inactivation of Cdk2 by promoting phosphorylation-dependent turnover of the Cdk activating phosphatase Cdc25A
-
CVT-313
-
inhibitor used in treatment of neointimal hyperplasia, IC50 for CDK1 is 0.004 mM, for CDK2 0.0005 mM, and for CDK4 0.215 mM
cyclin D1
-
inhibits the association and activation of androgen receptor by CDK6
-
cyclin-dependent kinase inhibitor 1B
-
protein CDKN1B, also called p27kip1
-
cyclin-dependent kinase inhibitor p27KIP1
-
-
-
deoxyvariolin B
-
-
DN-CDK2
-
suppresses CDK2 activity and partially increases erlotinib sensitivity
-
E2F1 peptide
-
81PALGRPPVKRRLDLE95
-
erlotinib
-
erlotinib treatment of breast cancer cells suppresses CDK2 activity; suppresses CDK2 activity, which is critical for cellular sensitivity to erlotinib, regardless of EGFR expression level. CDK1, CDK4 and CDK6 is not associated with erlotinib sensitivity
ethyl 4-[[1-methyl-3-(methylcarbamoyl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazolin-8-yl]amino]piperidine-1-carboxylate
-
-
ethyl [2-([[4-(1,3-benzothiazol-2-yl)thiophen-2-yl]sulfonyl]amino)-1,3-thiazol-4-yl]acetate
-
-
FAALS
-
five amino-acid peptide inhibitor that is directed toward a noncatalytic binding pocket and which disrupts the cdk2/cyklin E complex
fascaplysin
-
CDK4- and CDK6-specific inhibitor
fisetin
-
a flavonol inhibitor of CDK6, CDK5, and CDK1, binding structure with CDK6 involving V101, E61, K43, D163, and E99 of CDK6, overview
flavopiridol
-
inhibitor used in treatment of neointimal hyperplasia, IC50 for CDK1 is 0.0005 mM, for CDK2 0.0001 mM, for CDK4 0.000065 mM, for CDK6 0.00006 mM, and for CDK7 0.00011-0.0003 mM
flavopiridol
-
an effective flavonoid inhibitor of CDK6, CDK5, and CDK1
flavopiridol
-
-
flavopiridol
-
specific cyclin-dependent kinase inhibitor
flavopiridol
-
alvocidib
flavopiridol
-
non-specific CDK inhibitor
flavopiridol
-
maximal inhibition at 24 h with doses of 200 nM or higher
flavopiridol
-
-
flavopiridol
-
a potent CDK9 inhibitor
ginsenoside F1
-
noncompetitive inhibition
ginsenoside Rb1
-
noncompetitive inhibition
ginsenoside Re
-
noncompetitive inhibition
ginsenoside Rf
-
noncompetitive inhibition
ginsenoside Rg1
-
noncompetitive inhibition
ginsenoside Rg2
-
noncompetitive inhibition
ginsenoside Rh1
-
noncompetitive inhibition
H1PAla
-
noncompetitive inhibitor
-
H1PPO4
-
noncompetitive inhibitor
-
hymenialdisine
-
-
IkappaBalpha
-
human protein, competes with INK4 proteins for binding sites on CDK4, CDK4 is bound at the N-terminal ankyrin repeats, while the C-terminal ankyrin repeats bind NF-kappaB, structure analysis
-
indirubin 3'-monoxime
-
-
indirubin-3'-monoxime
-
82% inhibition of CDK2 at 0.01 mM
indirubin-3'-monoxime
-
-
indirubin-3'-oxime
-
-
indirubin-5-sulfonic acid
-
-
INK4 proteins
-
inhibit CDK4
-
insulin-like growth factor binding protein-3
-
decreases the phosphorylation activity of CDK2 and CDK4
-
isopentenyladenine
-
-
isopentenyladenine
-
potent inhibitor of CDK1/cyclin B
kaempferol
-
a less potent flavonoid inhibitor of CDK6, CDK5, and CDK1
kenpaullone
-
78% inhibition of CDK2 at 0.01 mM
KSLNRPFPDKIPELK
-
-
-
LAALS
-
; five amino-acid peptide inhibitor that is directed toward a noncatalytic binding pocket and which disrupts the cdk2/cyklin E complex
LiCl
-
slight inhibition of T231 phosphorylation by p25-Cdk5 kinase complex
luteolin
-
a flavonoid inhibitor of CDK5 and CDK1
membranes
-
of brain and liver, Cdk5-p35 is negatively regulated by interaction with membranes, mechanism
-
meridianin A
-
-
meridianin G
-
-
meriolin 1
-
-
meriolin 2
-
-
Myt1
-
Cdk1 inhibitor
-
N-(1-[4-[(5-fluoro-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-yl)amino]phenyl]azetidin-3-yl)acetamide
-
-
N-(2-methoxyethyl)-4-([4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino)benzenesulfonamide
-
;
N-(2-methoxyethyl)-4-([4-[2-methyl-1-(2-methylpropyl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino)benzenesulfonamide
-
;
N-(2-methoxyethyl)-4-[[4-(1,2,4-trimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide
-
;
N-(4-[4-[(2-methoxyethyl)sulfonyl]piperazin-1-yl]phenyl)-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-amine
-
-
N-(4-[[3-(dimethylamino)propyl]sulfonyl]phenyl)-4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-amine
-
;
N-(4-[[3-(dimethylamino)propyl]sulfonyl]phenyl)-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
-
;
N-(5-nitro-1H-indazol-3-yl)-2-phenylacetamide
-
-
N-(6-amino-pyrimidin-4-yl)-sulfanilic acid amide
-
-
N-1-dimethyl-8-([1-[(4-methylpiperazin-1-yl)carbonyl]piperidin-4-yl]amino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
N-1-dimethyl-8-[(1-methylpiperidin-4-yl)amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
N-1-dimethyl-8-[[1-(methylsulfonyl)piperidin-4-yl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
N-1-dimethyl-8-[[1-(phenylcarbonyl)piperidin-4-yl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
N-benzyl-8-(cyclopentylamino)-N-hydroxy-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
N-cyclohexyl-8-(cyclopentylamino)-N-hydroxy-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
N-methyl-4-[[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino]benzenesulfonamide
-
-
N-methyl-[4-[2-(7-oxo-6,7-dihydro-8H-[1,3]thiazolo[5,4-e]indol-8-ylidene)hydrazino]phenyl]methanesulfonamide
-
-
N-[(3R)-1-[4-[(5-fluoro-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-yl)amino]phenyl]pyrrolidin-3-yl]acetamide
-
-
N-[(9bR)-5-oxo-2,3,5,9b-tetrahydro-1H-pyrrolo[2,1-alpha]isoindol-9-yl]-N'-pyridin-2-yl urea
-
-
N-[(9bR)-5-oxo-2,3,5,9b-tetrahydro-1H-pyrrolo[2,1-alpha]isoindol-9-yl]-N'-{5-[(2S)-pyrrolidin-2-yl]-1H-pyrazol-3-yl urea
-
-
N-[2-(1-aminohydrazino)ethyl]-4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide
-
;
N-[2-(dimethylamino)ethyl]-4-[(4-imidazo[1,2-b]pyridazin-3-ylpyrimidin-2-yl)amino]benzenesulfonamide
-
;
N-[4-(4-[[(diethylamino)acetyl]sulfonyl]piperazin-1-yl)phenyl]-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-amine
-
-
N-[4-(4-[[(dimethylamino)acetyl]sulfonyl]piperazin-1-yl)phenyl]-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-amine
-
-
N-[4-(4-[[2-(dimethylamino)ethyl]sulfonyl]piperazin-1-yl)phenyl]-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-amine
-
-
N-[4-(benzylsulfonyl)phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
-
;
N-[4-[(2-methoxyethyl)sulfonyl]phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
-
;
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(3-fluorophenyl)acetamide
-
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(3-methylphenyl)acetamide
-
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-fluorophenyl)acetamide
-
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-hydroxyphenyl)acetamide
-
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-methylphenyl)acetamide
-
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-piperidin-1-ylphenyl)acetamide
-
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-pyridin-4-ylphenyl)acetamide
-
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-naphthalen-1-ylacetamide
-
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-naphthalen-2-ylacetamide
-
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-phenylacetamide
-
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-[4-(methylsulfanyl)phenyl]acetamide
-
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-[4-(methylsulfonyl)phenyl]acetamide
-
-
N-[5-(2,5-dioxoimidazolidin-1-yl)-1H-indazol-3-yl]-2-phenylacetamide
-
-
N-[5-(2-oxopiperidin-1-yl)-1H-indazol-3-yl]-2-phenylacetamide
-
-
N-[5-(2-oxopyrrolidin-1-yl)-1H-indazol-3-yl]-2-phenylacetamide
-
-
N-[5-(dibutylamino)-1H-indazol-3-yl]-2-phenylacetamide
-
-
N-[5-(diethylamino)-1H-indazol-3-yl]-2-phenylacetamide
-
-
N-[5-(dipropylamino)-1H-indazol-3-yl]-2-phenylacetamide
-
-
N-[5-(ethylamino)-1H-indazol-3-yl]-2-phenylacetamide
-
-
N2-(3-bromophenyl)-6-(cyclohexylmethoxy)-5-nitrosopyrimidine-2,4-diamine
-
-
N2-(3-bromophenyl)-6-(cyclohexylmethoxy)pyrimidine-2,4-diamine
-
-
N4-(6-aminopyrimidin-4-yl)-sulfanilamide
-
competitive inhibitor
N6-Dimethylaminopurine
-
unspecific inhibitor of protein kinases
NMDA
-
inactivates Cdk5 by modulation of Ser67 on the protein phosphatase inhibitor-I, overview
NU6102
-
highly potent and selective ATP-competitive inhibitor of CDK2
Olomoucine
-
-
Olomoucine
-
Cdk5 inhibitor, tau protein phosphorylation at S202, S235, and S404 is inhibited to a basal level
Olomoucine
-
decreases by ca. 30% the phosphorylation of parkin
Olomoucine
-
specific inhibitor of CDK1, 2, 5, and 7
Olomoucine
-
-
olomoucine II
-
-
oxindole-based compounds
-
highly selective for mrk, IC50 of mrk is 0.0015 mM, low cross-reactivity with PK5 and human CDK1
-
p15Ink4b
-
INK4 protein
-
p16
-
wild-type and D84A mutant human INK4 protein, the mutant is only slightly inhibitory, p16 has regulatory function on the CDK4/cyclin D2 activity, p16 competes with IkappaBalpha for binding sites on CDK4, structure analysis
p16
-
i.e. p16INK4, inhibits CDK4, not CDK2
p16(INK4a)
-
-
-
p16Ink4a
-
INK4 protein
-
p16Ink4a
-
inhibits the association and activation of androgen receptor by CDK6
-
p16Ink4a
-
as recombinant His-tagged protein
-
p18
-
wild-type and D76A mutant human INK4 protein, the mutant is only slightly inhibitory, p18 competes with IkappaBalpha for binding sites on CDK4, structure analysis
-
p18Ink4c
-
INK4 protein
-
p19Ink4d
-
INK4 protein
-
p21
-
induction of p21 by p53 leads to inhibition of Cdk2 and Cdk1 complexes
-
p21
-
-
-
p21
-
also named WAF1, SD1,or Cip1, specific inhibitor of CDK2, 4 and 6
-
p21 protein
-
i.e. Cip1 or Waf1, a Cdk-inhibitor
-
p21CIP
-
as recombinant GST-tagged protein
-
p21Cip1
-
inhibits phosphorylation of tumor suppressor Rb
-
p21Cip1
-
-
-
p21Clp1
-
forms a ternary complex with and is negatively regulated by p21Cip1, but not by its truncated fragment p21Cip1-D3
-
p21v1
-
endogenous CDK inhibitor
-
p21v2
-
endogenous CDK inhibitor
-
p21WAF1/CIP1
-
specific Cdk inhibitor, efficiently prevents etoposide-induced apoptotic cell death
-
p21WAF1/CIP1
-
potent CDK inhibitor
-
p27
-
;
-
p27
-
-
-
p27
-
endogenous CDK inhibitor
-
p27
-
a CDK inhibitor
-
p27Kip1
-
-
-
p27Kip1
-
-
-
p27Kip1
-
-
-
p27Kip1
-
as recombinant GST-tagged protein, formation of p27KIP1-cyclin A-CDK2 complex, the inhibitor interacts with both the cyclin and the CDK, analysis of the p27KIP1 docking site on cyclins, overview. p27KIP1 binds to the cyclin in a shallow groove where the hydrophobic amino acids of the MRAIL helix make multiple van der Waals contacts with p27KIP1
-
p27Kip1 cyclin-dependent-kinase inhibitor
-
-
-
p57KIP2
-
-
-
PHA-848125
-
-
-
Pho81 phosphoprotein
-
-
-
PKF049-365
-
-
pRb peptide
-
866SNPPKPLKKLRFDIE880
-
progesterone
-
-
protopanaxatriol
-
noncompetitive inhibition
purvalanol
-
98% inhibition of CDK2 at 0.01 mM
purvalanol
-
-
purvalanol A
-
-
purvalanol B
-
specific inhibitor of CDK1, 2, 5, and 7
quercetin
-
a less potent flavonoid inhibitor of CDK6, CDK5, and CDK1
RBG-286147
-
-
RNAi
Q9JHU3
depletion of PNQALRE by more than 80%, impairs cell proliferation, but fails to arrest the cell cycle at a discrete point
-
roscovitine
-
93% inhibition of CDK2 at 0.01 mM
roscovitine
-
complete inhibition of T231 phosphorylation by 25-Cdk5 kinase complex
roscovitine
-
inhibition of CDK5
roscovitine
-
inhibition in vitro and in vivo
roscovitine
-
Cdk5 inhibition induces neurotransmitter release in vivo
roscovitine
-
-
roscovitine
-
inhibition of IE63 protein phosphorylation at Ser224 leads to exclusive localization of IE63 protein in the host nucleus
roscovitine
-
inhibits Cdk5 activity, including the p35 phosphorylation activity
roscovitine
-
specific cyclin-dependent kinase inhibitor, inhibits cdk1, cdk2, cdk5, cdk7, and cdk9, no proteasome-dependent inhibition, time course of inhibition after treatment of infected cells in vivo, effects on viral replication, overview
roscovitine
-
inhibits Cdk2 activity which inhibits also the progesterone receptor activity in vivo
roscovitine
-
-
roscovitine
-
-
roscovitine
-
blocks the motility of prostate cancer cells in a wound healing assay
roscovitine
-
decreases by ca. 30% the phosphorylation of parkin
roscovitine
-
added at 24 h after human cytomegalovirus infection affects the accumulation of specific virus-encoded proteins
roscovitine
-
binds to the ATP binding pocket of Cdk2, preventing phosphate transfer from ATP to the protein substrate
roscovitine
-
0.05 mM
roscovitine
-
0.02 mM, potent Cdk5 inhibitor
roscovitine
-
0.015 mM
roscovitine
-
0.02 mM
roscovitine
-
specific inhibitor of CDK1, CDK1, CDK5, CDK7, and CDK9
roscovitine
-
seliciclib
roscovitine
-
Cdk5-p39 is inhibited by roscovitine at concentrations nearly identical to those that inhibit Cdk5-p35
roscovitine
-
competitive inhibitor
RXL motif-containing peptide
-
addition of this peptide significantly reduces substrate phosphorylation by cyclin E-CDK2 and cyclin D2-CDK6
-
shRNA
-
cdk5 shRNA is able to efficiently inhibit the expression of endogenous cdk5
-
Sic1
-
Cdk inhibitor, double-strand break is not efficiently repaired
-
simvastatin
-
inhibition of CDK2
siRNA
-
blocks the motility of prostate cancer cells in a wound healing assay
-
siRNA
-
inhibition of Cdk2, induces phosphorylation of ataxia-telangiectasia mutated substrates
-
siRNA
-
decreases by ca. 35% the phosphorylation of parkin
-
siRNA
-
knockdown of cdk5, results in a reduction in primary sensory neurons of the trigeminal ganglia of the peripheral nervous system, 80% loss of cdk5 protein in 10 hpf embryos
-
siRNA
-
knocking down of PFTK1 expression in SH-SY5Y cells, causes cell cycle arrest at G1
-
siRNA
-
knock down of Cdk2
-
SNS-032
-
formerly known as BMS-387032, SNS-032 exhibits potent and selective inhibitory activity against Cdk2, Cdk7, and Cdk9
staurosporine
-
-
staurosporine
-
potent inhibitor of CDK1/cyclin B
SU9516
-
inhibition in vitro and in vivo
TAACS
-
; five amino-acid peptide inhibitor that is directed toward a noncatalytic binding pocket and which disrupts the cdk2/cyklin E complex
TAALD
-
five amino-acid peptide inhibitor that is directed toward a noncatalytic binding pocket and which disrupts the cdk2/cyklin E complex
TAALE
-
five amino-acid peptide inhibitor that is directed toward a noncatalytic binding pocket and which disrupts the cdk2/cyklin E complex
TAALS
-
disrupts the cdk2/cyclin E complex
tranilast
-
inhibition of CDK2 and CDK4
tumour suppressor p16INK4a
-
-
-
variolin B
-
-
Wee1
-
Cdk1 inhibitor
-
[(2R)-1-[[4-(1,3-benzothiazol-2-yl)thiophen-2-yl]sulfonyl]pyrrolidin-2-yl]methanol
-
poor inhibition of cdk2/cyclin E
[8-(cyclopentylamino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazolin-3-yl](4-methylpiperazin-1-yl)methanone
-
-
meriolin 3
-
-
additional information
-
some cyclin-dependent kinases are inactivated by a complex of rapamycin with rapamycin-associated protein and FK506-binding protein
-
additional information
-
regulation by reversible phosphorylation, overview
-
additional information
-
autoregulation by a pseudosubstrate mechanism, overview
-
additional information
-
no inhibition of the p25-Cdk5 kinase complex by PD98059 and SB203580
-
additional information
-
no effect by doxycycline on enzyme expression and activity
-
additional information
-
T-cell protein tyrosine phosphatase phosphorylation by CDK-cyclin is not affected by diverse stress-inducing agents, hyperosmotic shock, cold shock, heat, oxidative stress, nocodazole, and anisomycin, as well as mitogens such as EGF and FBS
-
additional information
-
inhibition mechanism
-
additional information
-
integrin alpha1beta1 regulates phosphorylation of the axonal cytoskeleton protein, development of inhibitory peptides
-
additional information
-
negative feedback regulation mechanism via reduced stability, CDK-cyclin oscillates during the cell cycle, overview
-
additional information
-
physiological effects of CDK inhibition, overview, CDKs are deactivated by dephosphorylation, protein p27Kip1 mediates CDK2 inhibition
-
additional information
-
analysis of interactions between small molecule inhibitors with the ATP binding pocket of CDK2, determinations of binding structures and design of an inhibitor scaffold, overview
-
additional information
-
molecular modeling of inhibitor-enzyme interactions
-
additional information
-
IC50 values of pyrido[2,3-d]pyrimidin-7-one inhibitors on Cdk4/cyclin D1, Cdk1/cyclin B, Cdk2/cyclinA, and Cdk2/cyclin E, overview, antiproliferating activity of pyrido[2,3-d]pyrimidin-7-one inhibitors on MDA-MB-435 cells, overview
-
additional information
-
cell toxicity of the pyrazolo[3,4-c]pyridazine inhibitors on HeLa cells, overview, molecular modeling and analysis of binding structure of inhibitors to CDK2 using the CDK2 crystal structure, PDB code 1hck, modeling of ligand docking to the CDK2 structure, overview
-
additional information
-
IC50 values for CDK1-cyclin B with pyrazolo[3,4-c]pyridazine inhibitors, overview
-
additional information
-
structure-function relationship of flavonoid inhibitors, IC50 values, overview
-
additional information
-
enzyme cofactor p35 levels in primary embryonal cortical neurons are reduced by glutamate-induced stimulation of NMDA or kainate receptors through NMDA or kainate, p35 is reduced via proteasomal degradation, reduced p35 leads to inhibition of Cdk5, no inhibition by casein kinase inhibitor CKI-7
-
additional information
-
enzyme inhibition results in a decrease in virus titers in vivo, overview
-
additional information
-
R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine, i.e. SCH23390, or the PLCbeta antagonist 1-[6-([17beta-methoxyestra-1,3,5(10)-trien-17-yl]amino)hexyl]-1H-pyrrole-2,5-dione, i.e. U-73122, inhibit cdk5 transactivation by SKF83959 via the brain phosphatidylinositol-linked dopamin receptor, the transactivation is attenuated by calphostin C or by intracellular calcium chelator BAPTA
-
additional information
-
glutamate triggers the ubiquitination and subsequent degradation of p35 in neurons after autophosphorylation of Cdk5-p35 at p35
-
additional information
-
CDK is inhibited by phosphorylation through somatic Wee1A in M phase
-
additional information
-
CDK2 is inhibited by phosphorylation at Y14 and/or Y15 in the glycine-rich loop causing opening of the substrate binding box and affects binding of ATP
-
additional information
-
inhibition of Cdk2 by inactivation of Cdc25 phosphatases
-
additional information
-
after irridation of one- or two-cell embryos the cdk1/cyclin B1 complex is blocked
-
additional information
-
CDK inhibitor p16INK4a fails to interact with PFTK1; p16INK4a fails to interact with PFTK1
-
additional information
-
dysregulation of Cdk5 occurs with aging and concomitantly with an increase in DNA damage
-
additional information
-
acetylation markedly reduces both the kinase function and transcriptional activity
-
additional information
-
not inhibited by the CDK inhibitor p21
-
additional information
-
inhibitor synthesis and evaluation of inhibitory potencies with cdk2/cyclin E and cdk5/p25, overview
-
additional information
-
inhibitor synthesis and screening, docking study, overview
-
additional information
-
CDK-inhibitor-cyclin interaction mutational analysis, overview. Analysis of the inhibitor p27KIP1 docking site on cyclins, overview. Loss of p27KIP1 (or p21CIP) binding to the mutant cyclin D2-CDK complex, but not of p16INK4a
-
additional information
-
docking of CIP/KIP inhibitors and surface region involved, overview
-
additional information
-
evaluation of series of pyrazolo[4,3-h]quinazoline-3-carboxamides as inhibitors using diverse protein kinases, the compounds are active against CDK2/cyclin A, overview
-
additional information
-
nonionic detergent to solubilize Cdk5-p35 changes the kinase properties. Cdk1 is inhibited by Thr14/Tyr15 phosphorylation by the Wee1 family of kinases
-
additional information
-
ginsenosides as inhibitors of cyclin-dependent kinase 5/p25, structure-activity relationships, overview. Ginsenosides Rd, F2, Rb3, Rb2, Rg3, Rc, and Rh2 are no inhibitors of Cdk5/p25. No inhibition by protopanaxadiol
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
2,5-hexanedione
-
CDK5 contents and activities in sciatic nerve of rats treated with 200 or 400 mg/kg 2,5-hexanedione are significantly increased in both the cytosolic and membrane fractions, increase of CDK5 content in both the cytosolic and membrane fractions of spinal cord in 200 and 400 mg/kg 2,5-hexanedione-treated rats are observed
beta-amyloid peptide25-35
-
-
-
Calmodulin
-
Ca2+/calmodulin induce the phosphorylation of p35 by Cdk5 after stimulation of the Ca2+-permeable cation channels NMDA receptor and kainate receptor, leading to cleavage of p35 to p25
CDC25 phosphatase
-
major activator of CDK2
-
Cdc25A
-
-
-
CDK-activating kinase
-
the CDK-activating kinase (having three subunits, CDK7, cyclin H, and MAT1) plays a critical role in regulating cell cycle by mediating the activating phosphorylation of CDK1, CDK2, CDK4, and CDK6
-
CHAPS
-
the detergent increases Cdk5-p35 activity with histone H1 and the autophosphorylation at p35
Cks2
-
Cks 2 proteins activates Cdk2
-
Clbp1-Clbp6
-
cyclins, possible regulatory subunits of Cdc28p, each influencing the enzyme activity in a distinct way, overview
-
cyclin
-
dependent on
-
cyclin
-
e.g. cyclin A and cyclin B, dependent on, forms a subunit of the enzyme after binding
-
cyclin
-
dependent on
-
cyclin
-
dependent on, forms complexes with cyclin A
-
cyclin
-
dependent on
-
cyclin
-
different B-type cyclins are substantially redundant for rereplication control by multiple mechanisms. S-phase cyclin Clb5 and the mitotic cyclins Clb1-4 are inferred to be capable of imposing ORC-based and MCM-based controls. S-phase cyclin Clb6 can promote initiation of replication without blocking reinitiation, activity is highly toxic when the ability of other cyclins to block reinitiation is prevented by mutation
-
cyclin
-
stimulates, does not affect autophosphorylation
-
cyclin
-
-
-
cyclin A
-
cdk2 is dependent on, required as activating subunit, complexes with cdk2
-
cyclin A
-
dependent on
-
cyclin A
-
cyclin A/Cdk2 activity selectively increases during the early stages of etoposide-induced apoptosis
-
cyclin A
-
Cdk2/cyclin A complex formation is proportional to total cyclin A levels
-
cyclin A
-
-
-
cyclin A
-
activates Cdk2
-
cyclin A
-
required for CDK2 activity
-
cyclin A
-
activates Cdk2
-
cyclin B
-
activates CDK1
-
cyclin B
-
required for CDK1 activity
-
cyclin B
-
-
-
cyclin B
-
activates CDKA
-
cyclin Cln3
-
stability of Cln3 protein is diminished in strains with low activity of Pho85, a phosphate-sensing CDK. Cln3 is an in vitro substrate of Pho85, and both proteins interact in vivo. In vivo phosphorylation of S449 and T520 is essential to maintain Cln3 levels, Pho85 activity increases the half-life of Cln3 protein
-
cyclin D1
-
CDK4 is dependent on
-
cyclin D1
-
-
-
cyclin D2
-
-
-
cyclin D3
-
i. e. CCND3, enhances phosphorylation of tumor suppressor Rb
-
cyclin D3
-
-
-
cyclin E
-
enhances Cdk activity, overexpression activates the DNA damage response in U2-OS osteogenic sarcoma cells
-
cyclin E
-
-
-
cyclin E
-
activates Cdk2
-
cyclin E
-
required by cdk2
-
cyclin E
-
required for activity
-
cyclin E
-
activates Cdk2
-
cyclin E
-
required for activity of Cdk2, cyclin E is an oncoprotein implicated in breast cancer etiology that triggers the DNA damage response
-
cyclin H
-
activates Cdk7
-
cyclin I
-
-
-
cyclin T
-
CDK9 activating partner cyclin T1
-
cyclin T1
-
activates Cdk9
-
dynein light chain 1
-
interacts with cdk2 and enhances Cdk2 kinase activity in vivo, dynein light chain 1 accelerates the G1-S transition by enhancing the activity of Cdk2
-
E2F1
-
-
-
etoposide
-
activity of Cdk2 selectively increases after 6-9 h and then continues to increase over the 24 h time course of etopside treatment
ginsenoside Rb1
-
attenuates beta-amyloid peptide25-35-induced CDK5 activation
N-acetylcysteine
-
10 mM, increases cyclin-dependent kinase 5 phosphorylation, phosphorylation of Cdk5 on tyrosine 15 by c-Abl increases kinase activity of the p35/Cdk5 complex
Ndd1p
-
regulatory coactivator, Fkh2p phosphorylation by Cdc28p is regulated by complex formation with Mcm1p and Ndd1p, and phosphorylation
-
neuregulin
-
activates phosphorylation of STAT3 in vivo
-
NP-40
-
the detergent increases Cdk5-p35 activity with histone H1 and the autophosphorylation at p35
p25
-
inducible cytotoxic expression factor required for Cdk5 activity, formation of a complex with Cdk5, p25 overexpression increases tau phosphorylation rate
-
p25
-
activator required for CDK5 activity, activation of CDK5 by p25 which is activated by cleavage of p35 to p25
-
p25
-
cyclin activator, dependent on, over 10fold increase in activity of CDK5; regulatory and activating subunit, soluble localization of enzyme complex
-
p25
-
regulatory subunit and activator of Cdk5, soluble, p35 is cleaved to p25 by calpain leading to hyperactivation of Cdk5
-
p25
-
regulatory subunit of Cdk5
-
p25
-
soluble cofactor of Cdk5, cleavage of p35 to p25
-
p25
-
interacts with CDK5
-
p25
-
-
-
p25
-
primes tau protein for GSK3beta in vivo
-
p25
-
physically interacts with ligand-bound glucocorticoid receptor in vitro through the C-terminal portion enclosed by amino acids 190 and 262, p25 with a much stronger effect than p35 on suppression of glucocorticoid receptor transcriptional activity
-
p25
-
increased calpain activity in sensory neurons after inflammation results in the cleavage of p35 to p25, which forms a more stable complex with Cdk5 and, consequently, leads to elevation of Cdk5 activity
-
p25
-
regulatory subunit, binding of p25 to Cdk5 forces the activation loop to adopt an extended conformation typical of active proline-directed kinases
-
p25
-
regulatory subunit
-
p25
-
required for activity
-
p34SEI-1
-
i.e. TRIP-Br1, the protein binds directly to CDK4 and activates it at lower concentrations, but inhibits the enzyme at higher concentrations, p34SEI-1 has regulatory function, the binding is not affected by INK4 proteins p16 and p18, complex formation of CDK4, cyclin D2, p16, and p34SEI-1, p34SEI-1 has a LexA-mediated transactivation activity, determination of functional sequence units/fragments in the protein, overview
-
p35
-
tightly bound neuronal activators of cdk5, required for activity with regulatory function, p39 activates to a greater extent compared to p35 in vitro
-
p35
-
regulatory and activating subunit, particulate localization of enzyme complex
-
p35
-
regulatory subunit and activator of Cdk5
-
p35
-
regulatory subunit and activator of Cdk5, membrane-bound, in neuronal growth cones, p35 is cleaved to p25 by calpain leading to hyperactivation of Cdk5
-
p35
-
regulatory subunit and activator of Cdk5
-
p35
-
the cyclin is the regulatory subunit, dependent on
-
p35
-
membrane-bound cofactor of Cdk5, levels in primary embryonal cortical neurons are reduced by glutamate-induced stimulation of NMDA or kainate receptors through NMDA or kainate, cleavage of p35 to p25, reduced p35 leads to inhibition of Cdk5
-
p35
-
regulatory subunit of Cdk5
-
p35
-
regulatory activating cofactor of cdk5
-
p35
-
regulatory subunit of Cdk5
-
p35
-
activation subunit, required, interacts with and activates Cdk5, laminin induces upregulation of p35, regulation of p35 expression, overview
-
p35
-
primes tau protein for GSK3beta in vivo
-
p35
-
physically interacts with ligand-bound glucocorticoid receptor in vitro through the C-terminal portion enclosed by amino acids 190 and 262
-
p35
-
p35 knockout mice (p35-/-), which exhibit significantly decreased Cdk5 activity, show delayed responses to painful thermal stimulation compared with wild-type controls. In contrast, mice overexpressing p35, which exhibit elevated levels of Cdk5 activity, are more sensitive to painful thermal stimuli than are controls
-
p35
-
activation is dependent on non-cyclin activator p35
-
p35
-
principal activator
-
p35
-
Cdk5 activity is dysregulated by cleavage of activator p35 to p25 by calpain
-
p35
-
activation of Cdk5 requires association with two noncyclin neural-specific activators p35 and p39
-
p35
-
monomeric Cdk5 has no enzymatic activity and requires association with a regulatory binding partner p35 for its activation
-
p35
-
-
-
p35
-
activator protein of CDK5
-
p35
-
p35 or p39 are required by cdk5
-
p35
-
regulatory subunit, p35 is cleaved to p25 by calpain
-
p39
-
tightly bound neuronal activators of cdk5, required for activity with regulatory function, p39 activates to a greater extent compared to p35 in vitro, p39 is the activator activator in vivo
-
p39
-
regulatory subunit and activator of Cdk5
-
p39
-
regulatory activating cofactor of cdk5
-
p39
-
activation subunit, can substitute for p35, interacts with and activates Cdk5
-
p39
-
activation is dependent on non-cyclin activator p39
-
p39
-
principal activator
-
p39
-
activation of Cdk5 requires association with two noncyclin neural-specific activators p35 and p39
-
p39
-
-
-
p39
-
p35 or p39 are required by cdk5
-
p39
-
regulatory subunit, an isoform of p35 with high homology but a larger C-terminal domain, and low homology in the N-terminus including a myristoylation site and a Lys-cluster in amino acids 75-85
-
p39
-
regulatory subunit, Mice lacking p39 display an apparently normal phenotype
-
p58
-
regulatory subunit of CDK11
-
PfMAT1
-
stimulates Pfmrk kinase activity in a cyclin-dependent manner, does not affect autophosphorylation
-
progestin
-
-
Protein phosphatase 2A
-
PP2A, enhances CDK8 kinase activity in vitro for the RNA polymerase II carboxy-terminal domain but not for histone H3. PP2A enhancement of CDK8 is independent of RV-cyclin expression and likely plays a role in the normal regulation of CDK8
-
RV-cyclin
-
retroviral cyclin from Walleye dermal sarcoma virus, enhances CDK8 kinase activity in vitro for RNA polymerase II carboxy-terminal domain and histone H3. It is specific for cdk8, no activation of Cdk7 or Cdk9. The majority of the RV-cyclin structure is comprised of a cyclin box fold, which is responsible for binding to cyclin-dependent kinase-8. Two-hybrid interaction analysis in Saccharomyces cerevisiae strain Y190
-
Triton X-100
-
the detergent increases Cdk5-p35 activity with histone H1 and the autophosphorylation at p35
Tween 20
-
the detergent increases Cdk5-p35 activity with histone H1 and the autophosphorylation at p35
Mcm1p
-
regulatory coactivator, Fkh2p phosphorylation by Cdc28p is regulated by complex formation with Mcm1p and Ndd1p, and phosphorylation
-
additional information
-
regulation by reversible phosphorylation, activation by e.g. CAK, i.e. cyclin-dependent kinase activating kinase, overview
-
additional information
-
autoregulation by a pseudosubstrate mechanism, overview
-
additional information
-
phosphorylation regulates the enzyme activity, cyclin activating kinase CAK phosphorylates Thr160 of cdk2 leading to activation of cdk2
-
additional information
-
activation of cyclin-dependent kinase 4 by mouse MO15-associated kinase
-
additional information
-
thapsigargin-induced apoptosis might enhance the phosphorylation of the PHF-1 epitope of tau protein by CDK5-p25, no effect by doxycycline on enzyme expression and activity
-
additional information
-
T-cell protein tyrosine phosphatase phosphorylation by CDK-cyclin is not affected by diverse stress-inducing agents, hyperosmotic shock, cold shock, heat, oxidative stress, nocodazole, and anisomycin, as well as mitogens such as EGF and FBS
-
additional information
-
Cdk5 is activated by phosphorylation, integrin alpha1beta1 regulates phosphorylation of the axonal cytoskeleton protein
-
additional information
-
CDK is phosphorylated by a CDK-activating kinase, positive feedback by Cdc25, Wee1, and CAK is involved in CDK regulation
-
additional information
-
CDKs are activated by phosphorylation
-
additional information
-
CDK2 is activated by phosphorylation and cyclin binding
-
additional information
-
the proteasomal inhibitor lactacystin induces the Cdk-dependent phosphorylation of the retinoblastoma protein
-
additional information
-
activation mechanism and pathway of Cdk1/cyclin B, overview
-
additional information
-
6-chloro-7,8-dihydroxy-3-methyl-1-(3-methyl-phenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine, i.e. SKF83959, induces transctivation of cdk5 via the brain phosphatidylinositol-linked dopamine receptor, which is inhibited by SCH23390 or U-73122
-
additional information
-
CDKF,1 is activated by phosphorylation at the activation T-loop by CDK-activating kinases, CAKs
-
additional information
Q9JHU3
cyclin H or cyclin H together with cyclin K do not activate PNQALRE
-
additional information
-
Chk1 inhibition augments Cdk activity
-
additional information
P24100
phosphorylation of T161 in CDKA.1 is essential for cell division during male gametophyte development
-
additional information
-
phosphorylation of T161 in plant CDKA is required for activation of its associated kinase; phosphorylation of T161 is required for CDKA activation
-
additional information
-
inflammation increases Cdk5 activity
-
additional information
-
Cdk activating kinase
-
additional information
P97377
myocardial ischemia activates Cdk2 resulting in the phosphorylation and inactivation of the retinoblastoma gene product
-
additional information
-
full activation of CDK2 requires both binding of cyclin A or cyclin E and phosphorylation of residue T160 in the activation segment (also known as the T-loop) by the CDK-activating kinase
-
additional information
-
cardiac CDK9 is initially activated by hypertrophic stimuli
-
additional information
-
the anomalous cdk5/p25 complex is active
-
additional information
-
substrate phosphorylation by CDK6 with K-cyclin from Kaposi sarcoma herpesvirus, K-cyclin expression in U2OS cells leads to fragmentation of actin stress fibers. CDK-cyclin and CDK-inhibitor-cyclin interaction mutational analysis, overview. Analysis of the inhibitor p27KIP1 docking site on cyclins, overview
-
additional information
-
Cdk5 requires the binding of p35, p25 (a C-terminal fragment of p35), or p39 as regulatory subunnits for activation, activation mechanism of Cdk5, overview. Proteasomal degradation of p39 is several times slower than that of p35, and the cleavage rate is also slow for p39, implicating a smaller contribution of p39 to neurodegenerative diseases
-
additional information
-
Cdk5 Cdk5 requires the binding of p35, p25 (a C-terminal fragment of p35), or p39 as regulatory subunnits for activation, activation mechanism of Cdk5, overview
-
additional information
-
interaction of RV-cyclin with protein phosphatase 2A, overview
-
additional information
-
poor activation of CDKA with cyclin D
-
KM VALUE [mM]
KM VALUE [mM] Maximum
SUBSTRATE
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
0.046
-
ADAQHATPPKKKRKVEDPKDF
-
pH 7.4, Cdk1-as1/cyclin 2B
0.521
-
ADAQHATPPKKKRKVEDPKDF
-
pH 7.4, Cdk1-as1/cyclin 5B
0.00522
-
ATP
-
pH 7.5, 37C
0.017
-
ATP
-
in 20 mM MOPS (pH 7.5), at 30C
0.00285
-
PKTPKKAKKL
-
pH 7.5, 37C
0.003
-
Fin1
-
pH 7.4, Cdk1-as1/cyclin 5B
-
additional information
-
additional information
-
multisite phosphorylation and network dynamics of cyclin-dependent kinase signaling in the eukaryotic cell cycle, mathematical modeling of the enzyme complex behaviour, calculation of kinetics and dynamics, overview
-
additional information
-
additional information
-
kinetics of Cdk1-As1 mutant with cyclins 5B and 2B in reaction with different substrates, overview
-
TURNOVER NUMBER [1/s]
TURNOVER NUMBER MAXIMUM[1/s]
SUBSTRATE
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
1.9
-
ADAQHATPPKKKRKVEDPKDF
-
pH 7.4, Cdk1-as1/cyclin 5B
3.15
-
ADAQHATPPKKKRKVEDPKDF
-
pH 7.4, Cdk1-as1/cyclin 2B
0.28
-
ATP
-
in 20 mM MOPS (pH 7.5), at 30C
1.7
-
Fin1
-
pH 7.4, Cdk1-as1/cyclin 5B
-
Ki VALUE [mM]
Ki VALUE [mM] Maximum
INHIBITOR
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
0.00015
-
(5Z)-2-(benzylamino)-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.00031
-
(5Z)-2-(butylamino)-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.00027
-
(5Z)-2-(cyclopropylamino)-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.002
-
(5Z)-2-(methoxyamino)-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
Ki above 0.002 mM
0.00027
-
(5Z)-2-(methylamino)-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.002
-
(5Z)-2-(phenylamino)-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
Ki above 0.002 mM
0.00104
-
(5Z)-2-[(2,6-dichlorobenzyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.000038
-
(5Z)-2-[(2-bromobenzyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.000052
-
(5Z)-2-[(2-chlorobenzyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.000086
-
(5Z)-2-[(2-methoxybenzyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.00006
-
(5Z)-2-[(2-phenylethyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.00028
-
(5Z)-2-[(2-pyridin-2-ylethyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.00039
-
(5Z)-2-[(3-hydroxy-2-phenylpropyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.00024
-
(5Z)-2-[(3-phenylpropyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.00031
-
(5Z)-2-[(pyridin-2-ylmethyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.002
-
(5Z)-2-[methyl(thiophen-2-ylmethyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
Ki above 0.002 mM
0.00023
-
(5Z)-2-[[(1R)-1-benzyl-2-hydroxyethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.00035
-
(5Z)-2-[[(1R)-2-hydroxy-1-phenylethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.002
-
(5Z)-2-[[(1R)-2-methoxy-1-phenylethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
Ki above 0.002 mM
0.000023
-
(5Z)-2-[[(1R,2S)-2-phenylcyclopropyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.002
-
(5Z)-2-[[(1S)-1-benzyl-2-hydroxyethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.00058
-
(5Z)-2-[[(1S)-2-hydroxy-1-phenylethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.000046
-
(5Z)-2-[[2-(2-chlorophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.000087
-
(5Z)-2-[[2-(2-ethoxyphenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.00012
-
(5Z)-2-[[2-(2-fluorophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.000063
-
(5Z)-2-[[2-(2-methoxyphenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.00013
-
(5Z)-2-[[2-(3-chlorophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.00006
-
(5Z)-2-[[2-(3-fluorophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.00064
-
(5Z)-2-[[2-(4-bromophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.00041
-
(5Z)-2-[[2-(4-chlorophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.000062
-
(5Z)-2-[[2-(4-fluorophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.00039
-
(5Z)-2-[[2-(4-methoxyphenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
-
0.000089
-
(5Z)-5-(quinolin-6-ylmethylidene)-2-(thiophen-2-ylmethyl)-1,3-thiazol-4(5H)-one
-
-
0.000045
-
(5Z)-5-(quinolin-6-ylmethylidene)-2-[(2-thiophen-2-ylethyl)amino]-1,3-thiazol-4(5H)-one
-
-
0.000035
-
(5Z)-5-(quinolin-6-ylmethylidene)-2-[(thiophen-2-ylmethyl)amino]-1,3-thiazol-4(5H)-one
-
-
0.012
-
NU2058
-
-
0.0013
-
NU6027
-
-
0.000006
-
NU6102
-
-
IC50 VALUE [mM]
IC50 VALUE [mM] Maximum
INHIBITOR
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
0.00027
-
(1S,2R,3R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2yl]amino]cyclohexane-1,2-diol
-
CDK5/p25, pH 7.5, 30C
-
0.00037
-
(1S,2R,3R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2yl]amino]cyclohexane-1,2-diol
-
CDK9/cyclin T, pH 7.5, 30C
-
0.00061
-
(1S,2R,3R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2yl]amino]cyclohexane-1,2-diol
-
CDK2/cyclin A, pH 7.5, 30C
-
0.00087
-
(1S,2R,3R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2yl]amino]cyclohexane-1,2-diol
-
CDK1/cyclin B, pH 7.5, 30C
-
0.00018
-
(2R)-2-hydroxy-3-[[9-(propan-2-yl)-6-[[4-(pyridin-2-yl)benzyl]amino]-9H-purin-2-yl]amino]propyl L-valinate
-
CDK5/p25, pH 7.5, 30C; CDK9/cyclin T, pH 7.5, 30C
0.00087
-
(2R)-2-hydroxy-3-[[9-(propan-2-yl)-6-[[4-(pyridin-2-yl)benzyl]amino]-9H-purin-2-yl]amino]propyl L-valinate
-
CDK2/cyclin A, pH 7.5, 30C
0.0014
-
(2R)-2-hydroxy-3-[[9-(propan-2-yl)-6-[[4-(pyridin-2-yl)benzyl]amino]-9H-purin-2-yl]amino]propyl L-valinate
-
CDK1/cyclin B, pH 7.5, 30C
0.00015
-
(2R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]propane-1,2-diol
-
CDK9/cyclin T, pH 7.5, 30C
-
0.00019
-
(2R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]propane-1,2-diol
-
CDK5/p25, pH 7.5, 30C
-
0.00048
-
(2R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]propane-1,2-diol
-
CDK2/cyclin A, pH 7.5, 30C
-
0.0006
-
(2R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]propane-1,2-diol
-
CDK1/cyclin B, pH 7.5, 30C
-
0.00037
-
(2S)-4-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]butane-1,2-diol
-
CDK1/cyclin B, pH 7.5, 30C
-
0.00082
-
(2S)-4-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]butane-1,2-diol
-
CDK5/p25, pH 7.5, 30C
-
0.00098
-
(2S)-4-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]butane-1,2-diol
-
CDK2/cyclin A, pH 7.5, 30C
-
0.00101
-
(2S)-4-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]butane-1,2-diol
-
CDK9/cyclin T, pH 7.5, 30C
-
0.033
-
(3-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]phenyl)acetonitrile
-
with isozyme CDK2
0.000045
-
(3-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]phenyl)methanol
-
with isozyme CDK2
0.00045
-
(3R,5S)-5-(hydroxymethyl)-1-[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]- purin-2-yl]pyrrolidin-3-ol
-
CDK9/cyclin T, pH 7.5, 30C
-
0.00061
-
(3R,5S)-5-(hydroxymethyl)-1-[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]- purin-2-yl]pyrrolidin-3-ol
-
CDK5/p25, pH 7.5, 30C
-
0.00065
-
(3R,5S)-5-(hydroxymethyl)-1-[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]- purin-2-yl]pyrrolidin-3-ol
-
CDK2/cyclin A, pH 7.5, 30C
-
0.00045
-
(3R,5S)-5-(hydroxymethyl)-1-[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]-purin-2-yl]pyrrolidin-3-ol
-
CDK1/cyclin B, pH 7.5, 30C
-
0.004
-
(3Z)-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
-
IC50 for mrk is 0.0040 mM, and for PK5 0.15 mM, only weak inhibition of parasite strains D6 and W2 growth
0.016
-
(3Z)-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
-
IC50 for CDK1 is above 0.016 mM
0.0035
-
(3Z)-3-[2-(4-bromophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
IC50 for mrk is 0.0035 mM, and for PK5 0.13 mM, only weak inhibition of parasite strains D6 and W2 growth
0.012
-
(3Z)-3-[2-(4-bromophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
IC50 for CDK1 is 0.012 mM
0.0031
-
(3Z)-5-bromo-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
-
IC50 for mrk is 0.0031 mM, and for PK5 0.12 mM, only weak inhibition of parasite strains D6 and W2 growth
0.03
-
(3Z)-5-bromo-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
-
IC50 for CDK1 is 0.030 mM
0.0014
-
(3Z)-5-bromo-3-[2-(4-fluorophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
IC50 for mrk is 0.0014 mM, and for PK5 0.19 mM, only weak inhibition of parasite strains D6 and W2 growth
0.029
-
(3Z)-5-bromo-3-[2-(4-fluorophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
IC50 for CDK1 is 0.029 mM
0.0029
-
(3Z)-5-bromo-3-[2-(4-methylphenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
IC50 for mrk is 0.0029 mM, and for PK5 0.12 mM, only weak inhibition of parasite strains D6 and W2 growth
0.029
-
(3Z)-5-bromo-3-[2-(4-methylphenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
IC50 for CDK1 is 0.029 mM
0.000064
-
(4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]phenyl)acetonitrile
-
with isozyme CDK2
0.024
-
(4-[[4-amino-6-(cyclohexylmethoxy)pyrimidin-2-yl]amino]phenyl)acetonitrile
-
with isozyme CDK2
0.00013
-
(R)-roscovitine
-
CDK2
0.00016
-
(R)-roscovitine
-
CDK5
0.00021
-
(R)-roscovitine
-
CDK2/cyclin A, pH 7.5, 30C
0.00023
-
(R)-roscovitine
-
CDK9/cyclin T, pH 7.5, 30C
0.00028
-
(R)-roscovitine
-
CDK5/p25, pH 7.5, 30C
0.00033
-
(R)-roscovitine
-
CDK1/cyclin B, pH 7.5, 30C
0.00045
-
(R)-roscovitine
-
CDK1
0.00049
-
(R)-roscovitine
-
CDK7
0.00074
-
(R)-roscovitine
-
CDK9